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Breast cancer is the most common malignancy in women in Western countries. It is a 
heterogeneous disease with varying biological characte istics and aggressiveness. 
Although understanding of breast cancer carcinogenesis is increasing and classification 
has improved, many aspects of tumorigenesis, molecular mechanisms, and prognostic 
evaluation remain to be elucidated. Family history is one of the strongest predisposing 
factors for breast cancer. In most populations, the known susceptibility genes explain only 
around 25% of all familial breast cancers. At least part of the unknown familial 
aggregation may be caused by several low-penetrance variants that occur commonly in the 
general population. Cyclins are cell cycle-regulating proteins that interact with cyclin-
dependent kinases. Cyclin expression oscillates during the cell cycle and is under strict 
control. In cancer cells, cyclin expression often becomes deregulated, leading to 
uncontrolled cell division and proliferation, one of the hallmarks of cancer. 
In this study, we aimed to investigate the role of cyclins in breast cancer predisposition, 
pathogenesis, and tumor behavior. The suitability of the tissue microarray (TMA) 
technique for cyclin assessment was studied in 200 breast cancer cases. Cyclin A 
immunohistochemistry was evaluated both on traditional large sections and on TMA, and 
the reproducibility of two readers’ results was examined. The concordances of the findings 
from large sections and TMA and of the two readers’ re ults were good. Histopathological 
correlations of cyclin A and correlations with progn sis were similar for both large 
sections and TMA. These findings indicate that TMA is a reliable method for studying 
cyclin expression in breast cancer. 
The expression of critical cell cycle G1/S transition phase regulators cyclin D1 and E were 
studied among 1348 invasive breast cancers on TMA. Familial BRCA1/2-negative tumors 
had significantly more often low cyclin E and high cyclin D1 expression than BRCA1/2–
related or sporadic tumors. In a logistic regression model, cyclin E and D1 expression, 
estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status, and 
early onset of disease were the factors most clearly distinguishing BRCA1 patients from 
other familial breast cancer patients. Unique cyclin E and D1 expression patterns among 






tumors may reflect different predisposition and pathogenesis in these groups and help to 
differentiate mutation-positive from mutation-negative familial cancers. 
When assessing cyclin expression with regard to breast cancer characteristics and 
prognosis, high cyclin E expression was associated with an aggressive breast cancer 
phenotype and was an independent marker of poor metastasis-free survival. High cyclin 
D1 was associated with high grade and high proliferation among ER-positive but with low 
grade and low proliferation among ER-negative breast cancers. Among ER-positive 
cancers not treated with chemotherapy, high cyclin D1 showed a trend towards shorter 
metastasis-free survival. These results suggest that different mechanisms may drive 
proliferation in ER-negative and -positive breast cancers and that cyclin D1 has a 
particularly important role in tumorigenesis of hormone receptor-positive breast cancer. 
The association of a commonly occurring cyclin D1 gene (CCND1) polymorphism, 
A870G (Pro241Pro), with breast cancer risk alone and in combination with estrogen 
metabolism enzyme catechol-o-methyltransferase (COMT) gene polymorphism 
Met108/158Val was examined among 1956 breast cancer cases and 1406 controls from 
two populations from Finland and Ontario, Canada. The CCND1 high enzymatic activity 
allele A was associated with increased breast cancer risk (OR 1.3 in Ontario and 1.4 in 
Finland), and the interaction of the high-activity alleles of CCND1 and COMT conferred 
an even higher risk (OR 2.2 and 1.7, respectively). These results show that CCND1 and 
COMT act synergistically to contribute to breast cancer progression and that individual 
risk for breast cancer can be altered by the combined effect of polymorphisms with low-
penetrance alleles. 
Cyclin B1 expression was studied among 1348 breast cancers on TMA. High cyclin B1 
expression was associated with aggressive breast cancer features, but had an independent 
impact on survival. Besides tumor size and nodal sttu , cyclin B1 was the only 
independent predictor of poor metastasis-free survival among chemotherapy-naïve 
patients. This is the largest study by far investigating the prognostic role of cyclin B1 in 
breast cancer, and the results suggest that cyclin B1 immunohistochemistry is a method 
that could easily be adapted for routine use and is an independent prognostic factor, 
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Breast cancer is a heterogeneous disease with varying b ological characteristics, 
aggressiveness, and prognosis. Breast cancer carcinogenesis is only partly understood, and 
although subclassification has proceeded, many aspects of tumorigenesis and molecular 
mechanisms are still unclear. 
Family history is one of the strongest predisposing factors for breast cancer. Known high- 
and low-penetrance risk genes explain only 25% of familial predisposition for breast 
cancer. At least some of the excess familial risk may be explained by commonly occurring 
low-penetrance polymorphisms that either alone or interacting with other polymorphisms 
or environmental factors modify the individual risk for breast cancer. Tumors of familial 
breast cancer patients not attributable to mutations in known high-penetrance genes 
BRCA1 or BRCA2 have not been extensively characterized but they seem to be of lower 
grade than BRCA1, BRCA2, or sporadic tumors and more often estrogen receptor- (ER) 
and progesterone receptor- (PR) negative and p53-positive than sporadic tumors. Learning 
more about the characteristics of tumors in this patient group can shed light on the 
pathogenesis and genetic background of familial tumors not attributable to BRCA1 or 
BRCA2 mutations as well as to help to identify them from mutation-positive familial 
breast cancers. 
Due to earlier diagnosis and effective adjuvant treatment, breast cancer prognosis has 
improved and more than 85% of breast cancer patients are alive five years after diagnosis. 
A small number of breast cancers still have a poor prognosis and despite adjuvant 
treatment metastasize and lead to death even shortly after diagnosis. Breast cancer 
prognosis is traditionally defined by tumor size, tumor grade, and nodal status. Of 
biological markers, hormone receptor and human epidermal growth factor receptor 2 
(HER2) status affect prognosis and responsiveness to treatment. A high proliferation rate 
seems to be associated with poor prognosis, but uncertainty remains about the optimal 
methods and cut-offs for measuring proliferation. Although adjuvant chemotherapy and 
endocrine treatment are generally well tolerated, they can cause acute side-effects and 
harmful long-term effects, and thus, overtreatment should be avoided. New prognostic 






Cyclins are proteins that regulate the cell cycle. Cyclin expression oscillates during the 
cell cycle and is under strict control. In cancer, cyclin expression often becomes 
deregulated. Cyclin overexpression can lead to uncontrolled cell division and proliferation 
and be one of the crucial mechanisms in cancer developm nt and progression. Cyclin 
expression can be detected by immunohistochemical staining and can provide information 
on biological characteristics and prognosis of the tumor. This study focuses on bringing 






2 REVIEW OF THE LITERATURE 
2.1 General aspects of breast cancer 
2.1.1 Epidemiology 
Breast cancer is the most common malignancy in women of industrialized countries. An 
estimated one million women worldwide are diagnosed each year with breast cancer, and 
it is the leading cause of cancer death. In Finland, more than 4000 new cases were 
diagnosed in 2006 (www.cancerregistry.fi). Of all female cancers, about one-third are 
breast cancers. Breast cancer affects primarily older women; only about 25% of breast 
cancers are diagnosed in women under 50 years of age (Brenner & Hakulinen 2004). The 
mean age at diagnosis is approximately 60 years. Known risk factors for breast cancer 
include family history, early menarche, nulliparity or late age at first birth, no history or 
short duration of breastfeeding, low number of children, late menopause, long-term use of 
postmenopausal hormone replacement therapy, benign proliferative breast disease e.g. 
atypical hyperplasia or sclerosing adenosis, carcinoma of the contralateral breast, obesity 
when postmenopausal, low physical activity, exposure to ionizing radiation, smoking, and 
alcohol abuse (reviewed in Oldenburg et al. 2007). 
2.1.2 Carcinogenesis 
Cancer is defined as abnormal and destructive growth f cells or tissue that is independent 
of an external growth signal. Malignant cancer cells do not require growth signals, are 
insensitive to negative growth inhibitory signals, are capable of avoiding apoptosis, have 
limitless proliferative capacity, possess angiogenesis, and are able to invade neighboring 
tissues and develop metastases. Cancer develops from a single cell, which after DNA 
damage begins to proliferate in an uncontrolled manner. Daughter cells acquire further 
DNA damage and receive a growth advantage. 
Cancer is a genetic disease of somatic cells that develops after a series of mutations in a 
cell. DNA damage leading to carcinogenesis does not occur randomly in the genome, but 






either gain-of-function mutations that activate oncgenes encoding proteins needed in cell 
growth, such as transcription and growth factors, or loss-of-function mutations that 
inactivate tumor suppressor genes inhibiting cell cycle-, proliferation-, and apoptosis-
associated events (Kinzler & Vogelstein 1997 & 1998). Tumor suppressor genes can be 
described as gatekeepers, caretakers, or landscaper. Gatekeepers exert functions that 
directly inhibit cell growth or promote death by apoptosis. Caretaker genes control the 
genomic integrity, and landscapers regulate the cellular microenvironment. 
Breast carcinogenesis is a multi-step process in which normal breast epithelium evolves 
via hyperplasia and carcinoma in situ into an invasive cancer, which eventually can 
disseminate via the lymphatic and vascular systems to form distant metastases (Beckmann 
et al. 1997). Each of these steps is thought to correlate with one or more mutations in 
either oncogenes or tumor suppressor genes. In sporadic breast cancer, these mutations are 
acquired and occur in somatic cells without an underlying germline mutation. Essential 
early events in sporadic breast carcinogenesis are mutational activation of such oncogenes 
as c-myc, cyclin D1 gene (CCND1), or HER2 (Nass et al. 1997, Ormandy et al. 2003, 
Owens et al. 2004). Overexpression of ER is also frequently observed in early breast 
cancer (Yager et al. 2006). After first events, the tumor progression can proceed through 
different pathways, and breast carcinogenesis may be different in tumors with different 
histopathological features (Bürger et al. 1999 & 2000). 
Oncogenes that commonly obtain somatic mutations in breast cancer include c-myc, 
CCND1, p53, HER2, and PTEN. Recent advances in sequencing and bioinformatics have 
made it possible to analyze the somatic mutations of a cancer on a large scale. These 
large-scale cancer genome studies have revealed that the mount of mutations in breast 
cancer development may be higher than previously thoug t (Sjöblom et al. 2006, Wood et 
al. 2007). In a typical breast cancer, as many as 80 mutations can be present at the time of 
clinical diagnosis, but less than 15 are usually considered essential for tumor initiation and 
progression (Wood et al. 2007). Mutated genes in the cancer genome include some very 
often mutated genes, as well as a larger amount of i frequently mutated genes. The breast 
cancer genome seems to contain different mutated genes than other cancers. Of the large 
amount of mutated genes, many share functions in the same pathways or their protein 






breast cancer genome analyses suggest new potential o cogenes or tumor suppressor 
genes, e.g. NF-κB pathway kinase IKBKE or chromodomain helicase DNA binding 
domain 5 (CHD5), in addition to the traditionally known breast cancer oncogenes (Wood 
et al. 2007). 
Estrogen has a crucial role in breast carcinogenesis. Increased risk for breast cancer is 
associated with an elevated blood level of endogenous estrogen as well as with exposure 
to exogenous estrogen and progestin through hormone replacement therapy (Oldenburg et 
al. 2007). In experimental animals, estrogen treatmn  has led to the development of 
mammary tumors (Shull et al. 1997). Recent evidence suggests that estrogen may play a 
role even in the development and progression of ER- negative breast cancer, and operate 
by mechanisms other than by binding the ER (Gupta et l. 2007). Estrogen seems to be 
capable of contributing to all phases of the carcinogenic pathway, although the exact 
mechanisms are not fully understood. The toxic catechol estrogen metabolites are 
hypothesized to cause direct DNA damage, and ER-mediated genomic and non-genomic 
signaling may induce cell proliferation and inhibit apoptosis (Yager et al. 2006). 
In hereditary breast cancer, one tumor suppressor gene has a germline pathological 
mutation. Inactivation of the second allele, in addition to the germline mutation present in 
the first allele, is an early event in the pathway towards cancer. This “two-hit” model of 
carcinogenesis has originally been suggested by Knudson (1971). Mutation of the second 
allele may result from damage by endogenous toxins or occur by chance during DNA 
replication, leading to loss of function of the tumor suppressor. Loss of heterozygosity 
(LOH) is a common way to lose the wild-type allele. A mutated tumor suppressor gene 
can also cause cancer by mechanisms that do not require losing both alleles: by dominant-
negative effect, which means that the mutated allele disturbs the function of the normal 
allele (Brachman et al. 1996, Kwabi-Addo et al. 2001, Chevenix-Trench et al. 2002), or by 
haploinsufficiency, i.e. the normal allele is insufficient for the proper function of the gene 
(Fero et al. 1998, Fodde & Smits 2001). 
Current understanding of differences in oncogenic pathways between hereditary and 
sporadic breast cancers is far from complete, but in the former tumorigenesis appears to 






the latter the early event is more frequently genomic amplification of only one allele of an 
oncogene (Kenemans et al. 2004). 
2.1.3 Tumor features and histopathological classifi cation 
Practically all breast cancers are adenocarcinomas derived from glandular tissue (Berg & 
Hutter 1995). The general architecture of the tumor defines the histological type. The main 
subtypes are ductal and lobular carcinomas. Invasive ductal carcinoma derives from 
epithelial cells lining the ducts and is the most common type, accounting for 
approximately 70% of breast cancers. Invasive lobular carcinoma is the second most 
common type (10-20%). Lobular carcinoma is formed from acinus cells located in 
terminal ducts. Lobular carcinoma has a slightly better prognosis than ductal carcinoma 
but the risk for contralateral breast cancer is higher than with other subtypes. Lobular 
carcinoma metastasizes into serosal surfaces, cerebrospinal fluid, bone marrow, uterus, 
and ovaries more often than the other subtypes. Medullary carcinoma accounts for 1-7% 
of all breast cancers and is characterized by solid sheets of large cells with prominent 
nucleoli and frequent mitosis, and a noninfiltrative (pushing) margin. Medullary 
carcinoma has a somewhat better prognosis than ductal or lobular carcinoma. Mucinous 
and tubular carcinomas represent 1-2% of breast cancers each. Mucinous carcinoma is a 
slowly growing carcinoma occurring in older women, and tubular carcinoma is a well-
differentiated carcinoma with an excellent prognosis. Papillary carcinoma accounts for 
less than 1% of breast cancers. 
Tumor histological grade defines the differentiation f the tumor cells. Grading is 
performed using the method by Bloom and Richardson (1957), modified by Elston and 
Ellis (1991). The histological grade is based on three features; tubule formation, nuclear 
pleomorphism, and mitotic count, and divides breast tumors into three categories. Grade I 
tumors are well, grade II tumors moderately, and grade III tumors poorly differentiated. 
Breast cancer staging is performed by TNM classification that describes the size and 
extent of the tumor (T), involvement of local lymph nodes (N), and distant metastases 
(M). The TNM classification was accepted and is being updated by the International 






The routine pathological classification of a breast tumor also defines the lymphatic or 
vascular channel invasion, infiltration into skin, presence and amount of estrogen and 
progesterone receptors, and expression of HER2 protein, and presence of HER2 gene 
amplification. The tumor is considered hormone receptor-positive if 10% or more of the 
cells are stained. Approximately 80% of breast cancers are ER-positive, and most of these 
tumors are also PR-positive. The proportion of hormone receptor-positive cancers seems 
to be rising. Hormone receptor-positive tumors are sensitive to endocrine treatment. HER2 
gene amplification leading to immunohistochemical overexpression is detected in around 
15-20% of breast cancers (Slamon et al. 1989, Ravdin & Chamness 1995, Owens et al. 
2004). Tumors with positive HER2 status relapse more ften and more rapidly than 
HER2-negative tumors (Joensuu et al. 2003). The proliferation rate of tumor cells and the 






Table 1 TNM classification of breast cancer (modified from UICC 2002) 
Primary tumor (T)
pTis carcinoma in situ
pT1 ≤2.0 cm
T1mic ≤0.1 cm
T1a >0.1 cm but ≤0.5 cm
T1b >0.5 cm but ≤1.0 cm
T1c >1.0 cm but ≤2.0 cm
pT2 >2.0 cm but ≤5.0 cm
pT3 >5.0 cm
pT4 direct extension to skin or chest wall
T4a extension to chest wall (not pectoralis muscle)
T4b edema or ulceration of the skin, satellite skin nodules
T4c both T4a and T4b
T4d inflammatory carcinoma
Regional lymph nodes (N)
pN0 no regional lymph node metastasis
pN1 metastasis in movable ipsilateral axillary lymph node(s)
N1mi  micrometastasis >0.2 mm but ≤2 mm
N1a  metastasis in 1-3 axillary lymph nodes
N1b micrometastasis in internal mammary nodes detected by sentinel lymph node dissection
N1c  metastasis in 1-3 axillary lymph nodes and
micrometastasis in internal mammary nodes detected by sentinel lymph node dissection
pN2
N2a metastases in 4-9 axillary lymph nodes
N2b metastasis in clinically apparent internal mammary lymph nodes in the absence of 
axillary lymph node metastases
pN3
N3a metastasis in 10 or more axillary lymph nodes or in infraclavicular lymph nodes
N3b metastasis in internal mammary lymph nodes and axillary lymph nodes, or in
3 or more axillary lymph nodes and micrometastasis in internal mammary lymph nodes
detected in sentinel lymph node dissection
N3c metastasis in ipsilateral supraclavicular lymph nodes
Distant metastases (M)
M0 no distant metastasis
M1 distant metastasis  
2.1.4 Molecular classification 
Recently, complementary DNA (cDNA) microarray-based gene expression profiling has 
brought a new classification of invasive breast cancers (Perou et al. 2000, Sørlie et al. 
2001 & 2003). Five distinct breast cancer subtypes as ociated with different clinical 
outcomes can be identified. Luminal A and luminal B subtype tumors are ER-positive and 
share features with luminal epithelial cells that arise from the inner layer of duct lining. 
Luminal A tumors have the highest expression of ER gene, and luminal B tumors show 






subtype is ER-negative and overexpresses HER2 protein. The fourth subtype resembles 
normal breast cells and is characterized by high expression of basal epithelial and low 
expression of luminal epithelial genes. The fifth subtype is basal-like, with ER-, PR-, and 
HER2-negative tumors that express basal cytokeratins (CK) 5/6 and 17. These tumors 
show characteristics of myoepithelial cells from the outer (basal) layer of breast ducts. 
Basal-like tumors have the highest proliferation rates and a poor prognosis (Foulkes et al. 
2004). Overall, little is known about the development of aggressive basal-like tumors. 
Whether ER is actually involved in the pathogenesis of these tumors is uncertain. 
2.1.5 Prognostic aspects 
Although breast cancer incidence has been on the rise, the mortality has not. Today, more 
than 85% of breast cancer patients are alive five yars after diagnosis 
(www.cancerregistry.fi), and an estimated 75% will survive. Risk for recurrence is highest 
during the first five years after diagnosis, but breast cancer can metastasize even 15-20 
years after diagnosis. The improved prognosis is due to earlier diagnosis and more 
effective adjuvant treatment (Berry et al. 2005). The most important prognostic factors in 
breast cancer are nodal status, tumor size, and histological grade. These traditional 
prognostic factors are used to identify breast cancer patients at high risk for recurrence 
who will potentially benefit from adjuvant chemotherapy (Singletary et al. 2002). Young 
age (<35 years) at diagnosis is an independent marker of poor prognosis (Dubsky et al. 
2002). Of biological markers, negative hormone receptor status and HER2 gene 
amplification predict poor outcome (Isaacs et al. 2001, Joensuu et al. 2003, Harris et al. 
2007). Lymphatic or vascular channel invasion and high proliferation rate (Dettmar et al. 
1997, Bryant et al. 1998, Jansen et al. 1998, Clahsen et al. 1999) are also associated with 
poor breast cancer survival. Although HER2 positivity alone predicts poor outcome, the 
so-called triple-negative (ER, PR, HER2) breast cancers seem to have a highly aggressive 
clinical course with short recurrence-free periods and poor overall survival (Dent et al. 
2007). A large number of additional prognostic tumor markers have been published, but 
for many markers the prognostic value has not been shown in subsequent studies, and thus 
the true prognostic value remains unclear, and these markers have not been adapted for 






may allow more specific prognostic evaluation than by immunohistochemical methods 
(van’t Veer et al. 2002, van de Vijver et al. 2002, Paik et al. 2004). At the moment, how 
much these methods supplement prognostic evaluation nd treatment decisions in clinical 
use is uncertain. 
Although breast cancer prognosis has improved and can be considered good, a small 
proportion of breast cancers behave aggressively and despite adjuvant treatment 
metastasize and lead to death shortly after diagnosis. Finding new prognostic markers 
could help in identifying these tumors more accurately and possibly uncover novel 
strategies for developing future targeted therapies. More precise prognostic evaluation can 
also help in making treatment decisions and avoiding overtreatment, and decreasing the 
exposure of patients who do not actually benefit from treatment to the side-effects of 
adjuvant therapies. 
Table 2 Definition of risk for recurrence by tumor markers. Adapted from the St. Gallen 
consensus meeting recommendations (Goldhirsch et al. 2007). 
Low-risk tumors
Node-negative and all of the following features:
pT ≤2cm, grade 1, absence of vascular invasion, ER- and/or PR-positive,
absence of HER2 overexpression or gene amplification, age ≤35 years
Intermediate-risk tumors
Node-negative and at least one of the following features:
pT >2cm, or grade 2-3, or presence of vascular invasion, or ER- or PR- 
negative, or HER2 overexpression or gene amplification, or age ≤35 years
Node-positive (1-3 nodes involved) and:
ER- and/or PR-positive and absence of HER2 overexpression or gene
amplification
High-risk tumors
Node-positive (1-3 nodes involved) and
ER- or PR-negative, or HER2 overexpression or gene amplification
Node-positive (4 or more nodes involved)  
2.1.6 Adjuvant treatment  
Patients treated with local resection or those who have undergone mastectomy and have a 
high risk for recurrence (tumor size more than 5 cm or more than three regional lymph 






significantly diminishes the risk of local relapse (Clark et al. 1996, Fisher et al. 2002, 
EBCTCG 2005). 
The majority of breast cancer patients nowadays are also advised to have adjuvant 
chemotherapy and/or endocrine treatment. Only patients considered to have a small risk 
(<10%) of recurrence (Goldhirsch et al. 2007) do not seem to benefit from adjuvant 
treatment. Recurrence risk and the need for adjuvant treatment are defined by the presence 
of the adverse prognostic factors described above; and these recommendations are updated 
regularly. Adjuvant treatment significantly reduces the risk of recurrence and improves the 
survival of moderate- and high-risk breast cancer patients, but also exposes patients to 
harmful side-effects. A future challenge is to tailor the treatment based on the biological 
profile of the tumor to identify patients who will optimally benefit from each regimen. 
Table 3 Adjuvant treatment for early invasive breast cancer. Modified from the St. Gallen 
consensus meeting recommendations (Goldhirsch et al. 2007). 
Recurrence risk Highly endocrine- Incompletely endocri ne- Endocrine-
responsive* responsive** non-responsive***
Small Endocrine treatment Endocrine treatment No treatment
Medium Endocrine treatment, Chemotherapy and Chemotherapy and
or chemotherapy and endocrine treatment trastuzumab if HER2-
endocrine treatment and trastuzumab if positive tumor
and trastuzumab if HER2-positive tumor
HER2-positive tumor
High Chemotherapy and Chemotherapy and Chemotherapy and
endocrine treatment endocrine treatment trastuzumab if HER2-
and trastuzumab if and trastuzumab if positive tumor
HER2-positive tumor HER2-positive tumor
* hormone receptor-positive breast cancer
** borderline hormone receptor positivity, or negative progesterone receptor 
*** hormone receptor-negative breast cancer  
Patients with hormone receptor-positive tumors are off red endocrine therapy either alone 
or in combination with chemotherapy (Goldhirsch et al. 2007). Endocrine treatment 
consists of tamoxifen or aromatase inhibitors (anastrozole, letrozole, and exemestane), 
alone or in combination. Tamoxifen treatment for five years after diagnosis diminishes the 
risk of recurrence by 50% and of breast cancer-related death by 31% (EBCTCG 2005). 
Treatment with aromatase inhibitors alone for five years, changing tamoxifen to aromatase 
inhibitors after 2-3 years, or continuing endocrine treatment with aromatase inhibitors for 






postmenopausal patients (Goss et al. 2003 & 2007, Coombes et al. 2004, Howell et al. 
2005, Coates et al. 2007, Kaufmann et al. 2007, Forbes et al. 2008). 
Adjuvant polychemotherapy containing an anthracycline regimen improves the survival of 
premenopausal high- or medium-risk patients by ~45% and of postmenopausal patients by 
~26% (EBCTCG 2005). Adjuvant chemotherapy with taxanes further improves outcome 
of the patients at the highest risk for recurrence but, is also more toxic. Taxane treatment 
improves recurrence-free survival of lymph node-positive patients by 17% and overall 
survival by 15% (De Laurentiis et al. 2008). At the moment, no predictive tumor features 
for chemotherapy response are in standard use. 
Patients who have breast cancer showing HER2 gene amplification benefit from adjuvant 
treatment with HER2 protein targeting antibody trastuzumab in combination with 
chemotherapy, and in the case of endocrine-responsive tumor, with endocrine treatment 
(Piccart-Gebhart et al. 2005, Romond et al. 2005, Joensuu et al. 2006, Smith et al. 2007). 
Trastuzumab seems to prevent half of recurrences of these patients. 
2.2 Familial background for breast cancer 
Family history is considered one of the strongest predisposing factors for breast cancer. 
First-degree relatives of a breast cancer patient have an approximately twofold risk for 
breast cancer compared with the general population. Ge etic factors may play a role in up 
to 30% of breast cancers, but known high-risk susceptibility genes explain only 20-30% of 
hereditary and 5% of all breast cancer incidences (Lichtenstein et al. 2000). 
2.2.1 Breast cancer risk in cancer predisposition s yndromes 
Certain rare autosomal-dominant cancer predisposition syndromes cause elevated breast 
cancer risk in addition to other cancer risks. Carrier women of p53 mutations in Li-
Fraumeni syndrome have a 28-56% risk for breast cancer by the age of 45 years 
(Chompret et al. 2000). Cowden syndrome is caused by tumor suppressor gene PTEN 
mutations and confers a 20-50% lifetime risk for breast cancer (Eng 2003). Women with 






age of 70 years (Hearle et al. 2006). These rare cancer predisposition syndromes explain 
less than 1% of all familial breast cancers. 
2.2.2 High-penetrance susceptibility genes BRCA1 an d BRCA2 
The most important predisposing high-penetrance genes are BRCA1 on 17q21 and 
BRCA2 on 13q12-13 (Miki et al. 1994, Wooster et al. 1995). Numerous mutations have 
been reported throughout the coding regions of these large genes. BRCA1 and BRCA2 
function in DNA repair (Yoshida & Miki 2004, Zhang & Powell 2005) and act as classical 
tumor suppressor genes. LOH is a common phenomenon in BRCA1/2-related tumors. 
Women carrying germline BRCA1 or BRCA2 mutation have a high lifetime risk for 
breast (50-90% and 40-80%, respectively) and ovarian c ncers (20-50% and 10-20%, 
respectively) (Antoniou et al. 2003). Mutations in BRCA1 and BRCA2 explain ~20% of 
familial breast cancers in Finland (Vehmanen et al. 1997, Vahteristo et al. 2001, 
Hartikainen et al. 2007). 
2.2.3 Low-penetrance susceptibility genes 
Checkpoint kinase 2 (CHEK2) is a signal transducer that plays a crucial role in response to 
DNA damage. CHEK2 1100delC variant is the first recognized low- or moderate-
penetrance susceptibility variant in breast cancer, onferring an approximately twofold 
increased risk (Meijers-Heijboer et al. 2002, Vahteris o et al. 2002). Other variants in 
CHEK2 have also been suggested in breast cancer predis osition, and at least the I157T 
seems to be associated with increased breast cancer risk (Cybulski et al. 2004, Kilpivaara 
et al. 2004). The BRCA2-binding protein PALB2 gene has recently been identified as a 
new susceptibility gene with a 2- to 4-fold hereditary risk for breast cancer (Rahman et al. 
2006, Erkko et al. 2007). BRIP1 (BACH1) is a BRCA1-associated helicase that 
participates in DNA double-strand break repair with BRCA1. BRIP1 germline mutations 
have also been shown to be associated with an approximately twofold increased breast 
cancer risk (Seal et al. 2006). These low- or moderate-penetrance breast cancer 






2.2.4 Familial breast cancer predisposition not exp lained by known 
susceptibility genes 
Even considering all known high- and low-penetrance breast cancer susceptibility genes, 
the genetic background of ~70-75% of familial breast cancers remains unknown. Studies 
are underway to discover new breast cancer susceptibility genes. A polygenic model in 
breast cancer susceptibility has also been suggested and can explain some of the residual 
familial breast cancer aggregation (Antoniou et al. 2002, Pharoah et al. 2002, Antoniou & 
Easton 2006). Low-penetrance variants that occur comm nly in the general population 
may individually confer a moderate breast cancer risk, but have a multiplicative effect 
when combined. These low-penetrance variants may also interact with environmental risk 
factors such as estrogen exposure. The strongest evidence for common breast cancer 
susceptibility alleles by far comes from a large collaboration study and implies that the 
D302H variant in the caspase 8 (CASP8) gene and the L10P variant in the transforming 
growth factor beta 1 (TGFB1) gene are associated with breast cancer risk and may explain 
0.3% and 0.2%, respectively, of the excess familial breast cancer risk in European 
populations (Cox et al. 2007). Furthermore, a large genome-wide association study has 
recently found five novel independent loci with strong and consistent breast cancer 
associations (Easton et al. 2007). Genes and variants causing this breast cancer risk are 
subjects for further research. 
2.2.4.1 COMT Met108/158Val polymorphism 
Estrogen has a critical role in breast cancer development. Estrogen stimulates transcription 
of genes essential in cell proliferation through estrogen receptor and is suggested to cause 
DNA damage via catechol estrogen metabolites (Zhu & Conney 1998). A number of 
polymorphisms have been depicted in enzymes involved in estrogen synthesis or 
metabolism. Such variants include catechol-o-methyltransferase (COMT), cytochrome P-
450 (CYP) 17, 19, 1A1, and 1B1, and glutathione S-transferase M1 (GSTM1) genes. No 
significant association with breast cancer risk in subsequent materials has been found for 
any of these variants, but the combined effect of some of the variants may confer breast 






Catechol-o-methyltransferase (COMT) is a phase two enzyme in estrogen metabolism that 
catalyzes these toxic catechol estrogen metabolites into methoxyestrogens (Zhu 2002). 
Detoxification of catechol estrogens happens mainly i  the liver, but also in peripheral 
tissues such as the breast. COMT is expressed in brai , liver, kidney, and peripheral 
tissues including the epithelium of the ducti and lobuli of normal breasts. In breast tumor 
tissue, COMT expression is elevated compared with in normal breasts (Tenhunen et al. 
1999). COMT activity varies among individuals (Weinshilboum & Dunnette 1981), and 
COMT gene has a commonly occurring A to G single-nucleotide polymorphism (SNP) 
(Met108/158Val) at position 1947 (rs 4680). This polymorphism produces two different 
alleles of COMT: Met and Val. The Val allele has been suggested to have a 3- to 4-fold 
higher enzymatic activity than the Met allele (Lotta et al. 1995, Lachman et al. 1996). 
2.2.4.2 COMT Met108/158Val polymorphism and breast cancer risk 
The COMT Met108/158Val polymorphism has a role in some neurological and 
psychiatric diseases, and its association with riskfor cancer has been studied widely. 
Higher risk for breast cancer has been suggested for MetVal and ValVal genotypes 
(Lavigne et al. 1997, Ahsan et al. 2004, Sazci et al. 2004, Gaudet et al. 2006), although all 
studies have not confirmed the association (Millikan et al. 1998, Thompson et al. 1998, 
Mitrunen et al. 2001, Wedren et al. 2003, Onay et al. 2006, Akisik et al. 2007). 
2.2.4.3 CCND1 G870A polymorphism 
Uncontrolled cell proliferation is one of the hallmarks of cancer. The cell cycle is the 
machinery that governs proliferation and growth of cells, thus, alteration in genes 
regulating the cell cycle could predispose to cancer. Cyclin D1 has a critical role in control 
of cell cycle G1 to S phase transition. Cyclin D1 coding gene CCND1 has a commonly 
occurring G to A polymorphism (G870A, Pro241Pro) at position 6962 (rs 603965) in exon 
4. The frequency of the A allele in the Caucasian population is approximately 44% and of 
the G allele 56%, but frequencies have varied in different populations (Sanyal et al. 2004). 
This polymorphism produces two alternatively spliced forms of a transcript with varying 






enzymatic activity and is hypothesized to be more stable than the product of the G allele 
(Betticher et al. 1995). 
2.2.4.4 CCND1 G870A polymorphism and cancer risk 
The CCND1 G870A A allele has been reported to be associated with increased risk for 
several cancers, including colorectal, esophageal, cardiac, bladder, head and neck, lung, 
prostatic, and renal cell carcinomas as well as leukemia (reviewed in Knudsen et al. 2006). 
The results have not been entirely consistent since some studies have shown no risk and 
increased risk for cancer has even been reported for the GG genotype. Thus, the effect of 
this polymorphism may vary in distinct tumor types, although differences in study designs 
can also explain some of the discrepancies. The highest risks have, however, been reported 
in most studies for the AA genotype. The relative risks have typically been modest, which 
can in part be expected for a common allele such as the A allele in CCND1 
polymorphism. The cancer risk with this low-penetrance variant could be modified by 
polymorphisms in other genes or environmental factors (Buch et al. 2005, Shu et al. 
2005). 
2.2.4.5 CCND1 G870A polymorphism in breast cancer 
Four studies have evaluated the association of CCND1 polymorphism with breast cancer 
risk (Grieu et al. 2003, Krippl et al. 2003, Försti e  al. 2004, Shu et al. 2005). None of 
these showed a significantly increased breast cancer risk; the patient samples in these 
studies were, however, rather small (200-500 breast cancer cases). Nor has any association 
between the CCND1 polymorphism and specific clinicopathologic features of breast 
cancers been reported. 
2.2.4.6 Interaction of CCND1 and COMT 
CCND1 and COMT polymorphisms share functions in the estrogen pathway. Negative 
feedback by the COMT high-activity allele results in higher estrogen level, which may in 
turn increase CCND1 expression. If the CCND1 high activity allele was more stable, the 






enhanced proliferation. A study investigating the interactions of different SNPs in genes 
involved in major cancer pathways suggested a significa t association with elevated breast 
cancer risk for the CCND1 G870A and COMT Met108/158Val polymorphism interaction 
(Onay et al. 2006). Thus, the interaction of these common variants was suggested to play a 
role in individual breast cancer risk. 
2.2.5 Histopathological features of familial breast  cancer 
Breast cancers of BRCA1 carriers differ from sporadic and familial non-BRCA1/2 
cancers. BRCA1–associated cancers seem to be of higher grade, more often ER-, PR-, and 
HER2-negative, p53-positive, aneuploid, of medullary histology, and diagnosed at a 
younger age than sporadic cancers (Eisinger et al. 1996, Breast Cancer Linkage 
Consortium 1997, Jóhansson et al. 1997, Armes et al. 1998, Noguchi et al. 1999, Lakhani 
et al. 2002, Eerola et al. 2005). Bilateral cancer is common in BRCA1 carriers. Expression 
of cell cycle regulator cyclin E has been higher and cyclin D1 expression lower than 
among sporadic cancers (Osin et al. 1998, Armes et al. 1999, Vaziri et al. 2001, Palacios et 
al. 2005), and also higher expression of basal cytokeratins seems to characterize BRCA1 
tumors as compared with sporadic ones (Lakhani et al. 2005). cDNA expression studies 
have shown that tumors of BRCA1 carriers are mostly of basal cell epithelial phenotype 
(Foulkes et al. 2003 & 2004, Sorlie et al. 2003). 
BRCA2–associated breast cancers have shown a phenotyp  between the BRCA1–
associated and sporadic tumors (Noguchi et al. 1999, Lakhani et al. 2002, van der Groep et 
al. 2006). In some studies, BRCA2–associated tumors have not differed from sporadic or 
familial non-BRCA1/2 tumors in terms of tumor grade, histology, or ER, PR, HER2, and 
p53 status (Noguchi et al. 1999, Lakhani et al. 2002, Eerola et al. 2005). Higher amount of 
ER positivity and higher grade among BRCA2 tumors than among unselected tumors has 
been suggested (Bane et al. 2007, Brekelmans et al. 2007). Bilateral cancer is more 
common also among BRCA2 carriers than sporadic breast cancer patients. cDNA studies 
have identified a distinct expression profile also for BRCA2 tumors (Hedenfalk et al. 
2001). Cyclin E expression among BRCA2 tumors has been higher than among sporadic 
tumors but both higher and lower cyclin D1 expression has been reported (Osin et al. 






Breast cancers of familial non-BRCA1/2 patients are not as well characterized as BRCA1- 
or BRCA2–associated cancers. Three studies have invest gated histopathological features 
of these tumors. They seem to be of lower grade than BRCA1, BRCA2, or sporadic 
tumors (Lakhani et al. 2000, Eerola et al. 2005), and the most common histological type is 
invasive ductal carcinoma (Lakhani et al. 2000, Palacios et al. 2003, Eerola et al. 2005). 
Higher proportions of ER- and PR-negative and p53-positive tumors have been described 
among familial non-BRCA1/2 tumors than among sporadic tumors (Palacios et al. 2003). 
Based on the expression profiles of 60 different genes, a cDNA study divided the non-
BRCA1/2 tumors into two groups with varying aggressiveness (Hedenfalk et al. 2003). 
2.2.6 Identification of high-risk families 
The screening of BRCA1 and BRCA2 mutations is laborious and expensive. The selection 
of patients to whom genetic testing is offered should be as accurate as possible. Finding 
mutation-positive patients is essential since after the familial mutation has been 
recognized, predictive genetic testing can be offered to healthy family members at risk of 
having inherited the mutation. Women carrying germline BRCA mutation are 
recommended to undergo regular surveillance, including monthly breast self-examination, 
clinical breast examination every six months, and breast imagining (mammography and 
ultrasound, and breast MRI if possible) once a year. Gynecologic surveillance consists of 
transvaginal ultrasound examination and serum CA-125 tumor marker measurement every 
6-12 months. Prophylactic operations (prophylactic mastectomy and/or salpingo-
oophorectomy) can also be considered. Screening can help to detect cancers at an earlier 
stage, and prophylactic operations have been shown t  reduce breast and ovarian cancer 
incidence (reviewed in Bermejo-Perez et al. 2007). 
The probability of finding BRCA mutation is evaluated mainly based on family history. In 
a Finnish breast cancer material consisting of patients with three or more first- or second-
degree relatives with breast or ovarian cancer (including the proband) or patients from 
families with two affected cases, the age of the youngest breast cancer patient and the 
number of patients with ovarian cancer in the family were the independent factors 
predicting BRCA mutation positivity (Vahteristo et al. 2001). A logistic model based on 






for finding BRCA1 or BRCA2 mutation as compared with 43% of all families. The mean 
probability was 55% for mutation-positive and 11% for mutation-negative families. 
Several other models have been constructed to evaluate mutation probability. 
Incorporating tumor pathology data into probability models may improve mutation 
prediction models (Farshid et al. 2006, James et al. 2006). 
2.3 Cell cycle 
The human cell cycle is a firmly controlled machinery that regulates cell entry into mitosis 
and DNA replication, and thus, cell division. Cell cycle consists of different phases: G1 
phase (preparation for DNA synthesis), S phase (DNA synthesis and replication), G2 
phase (the second gap), and M phase (mitosis). G0 (quiescence) is a biochemically 
different resting phase, where cells are kept in the absence of proliferation stimuli, but 
from which cells upon growth factor stimulation can re-enter into the active cell cycle 
(Sherr 1996). As cells receive enough environmental proliferation stimuli, they move from 
G1 to S phase. This G1/S transition is considered irr versible (Sherr 1996). The G2 phase 
is important for DNA replication and for the correction of errors in replication. 
Cyclin -dependent kinases (CDKs) regulate the cell cyc e and changes between different 
phases. CDK levels remain relatively constant through t the cell cycle, but they are 
activated and inactivated by periodic changes in levels of their binding proteins. Cyclins 
are cell cycle regulator proteins that activate cell ycle progression by binding to CDKs. 
Active cyclin-CDK complexes drive phosphorylation cas ades throughout the cell cycle. 
Cyclin D1-CDK4/6 and cyclin E-CDK2 complexes act predominantly on G1 phase, cyclin 
A-CDK2 on S and G2 phases, and cyclin B1-CDK1 on G2 phase and mitosis. CDK 
inhibitors (CKIs) consist of large amount of inhibit ng proteins, e.g. inhibitors of kinase 4 
(INK4) group inhibitors CDKN2A (p16 and p14), CDKN2B (p15), CDKN2C (p18), and 
CDKN2D (p19), and the second group of CIP/KIP (cyclin-dependent kinase inhibitory 
protein/kinase inhibitor protein) inhibitors CDKN1A (p21) and CDKN1B (p27) (Sherr & 
Roberts 1999). INK4s bind to CDK4 and CDK6 to prevent their association with cyclin 
D1. CIP/KIP inhibitors do not affect cyclin binding, but form complexes with the G1/S 






The most important target of cyclin-CDK phosphorylation is the retinoblastoma protein 
(pRb) and other retinoblastoma family proteins such as p107 and p130. Active pRb 
represses the transcription factors essential for G1/S transition. Thus, pRb is a negative 
cell growth regulator. Upon stimuli of proliferation factors, pRb becomes inactivated and 
transcription factors needed for G1/S transition are activated. The pRb 
hyperphosphorylation disrupts its association with E2F, and activated E2F mediates 
transcriptional activation required for G1 progression. Cyclin D1-CDK4/6 complex is 
upregulated early after mitogenic stimuli and initiates the phosphorylation and inactivation 
of pRb (Baldin et al. 1993). Cyclin E-CDK2 complex becomes activated later and is 
necessary in pRb phosphorylation in late G1 phase as well as in events leading to DNA 
synthesis (Sheaff et al. 1997, reviewed in Caldon et al. 2006). Recent data suggests that 
also the cell cycle reentry from G0 to G1 phase is regulated by specific retinoblastoma 
family proteins in association with specific E2F transcription factors. Cyclin C/CDK3 
complex controls the pRb suppression at this phase and seems to be critical in promoting 
cell exit from the quiescent G0 phase (Ren & Rollins 2004). The G0 to G1 transition, 
however, is incompletely understood. The factors controlling the activity and stability of 
the cyclin C/CDK3 complex and the Rb-independent mechanisms for cells to exit G0 
remain to be elucidated. 
During oncogenesis cell cycle control mechanisms become deregulated and cell division is 
uncontrolled (Sherr 1996). CDK deregulation is considered one of the key events in tumor 
cells gaining unstrained growth capacity. In breast cancer cells, the cell cycle machinery 
seems to be uncontrolled at multiple levels. Deregulation of G2/M phase transition is 
found, but the G1/S transition appears to be particularly important in many cell cycle 
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Figure 1 The human cell cycle (adapted from Sherr 1996). 
2.3.1 Cyclin A 
Cyclin A level in cells rises in early S phase and is essential for DNA replication and is 
also involved in G2/M transition (Zindy et al. 1992, Fan & Bertino 1997). Cyclin A/CDK2 
complex regulates the pRb function in S and G2 phases nd controls the initiation of DNA 
replication and timing of mitosis. Cyclin A overexpression is able to induce premature S 
phase induction, and removing cyclin A can block the S phase progression (Girard et al. 
1991). In the mid-M phase, cyclin A is degraded andits level falls rapidly. Elevated cyclin 
A expression has been observed in several malignancies, including breast cancer 
(Bukholm et al. 2001), and is associated with poor cancer outcome at least in sarcomas 






2.3.2 Cyclin A in breast cancer 
Cyclin A overexpression is common in breast cancer. High cyclin A is more frequent 
among large, ER-negative, high-grade, cyclin E-, Ki67-, HER2-, and p53-positive and 
cyclin D1-negative tumors, as well as among tumors of younger patients. High cyclin A 
expression has been reported to be associated with poor prognosis in breast cancer 
(Bukholm et al. 2001, Michalides et al. 2002, Michels t al. 2003, Poikonen et al. 2005), 
although all studies have not confirmed this (Kühling et al. 2003, Rudolph et al. 2003). 
One explanation for the discrepancy in results might be the varying methods used to 
define cut-off values in different studies. Moreover, the study populations have differed. 
No association between cyclin A and poor prognosis was seen in patient material 
including only lymph node-negative patients, suggesting cyclin A may play a more 
important role in aggressive breast cancer and metastatic disease. A study aimed at 
determining the optimal cut-off value of cyclin A to identify highly proliferating tumors 
with poor prognosis suggested the optimal cut-off value to be around 8% (Ahlin et al. 
2007). To assess optimal cut-off value, the material in this study was divided into two 
parts at cut-offs that were defined by splitting the material into deciles, and by calculating 
the relative risk (RR) for each of these cut-offs. The cut-off value of 8% corresponds to 
the 7th decile. In this study, cyclin A was an independent predictor of poor metastasis-free 
survival among patients not given adjuvant chemotherapy, but among patients receiving 
chemotherapy no significant association with prognosis was found. Based on these results, 
tumors with high cyclin A expression can be speculated to be particularly sensitive to 
chemotherapy. 
2.3.3 Cyclin B1 
Cyclin B1/CDK1 complex controls G2-M phase transition and is needed for initiation of 
mitosis (Pines & Hunter 1990). In cancer cells, cyclin B1 expression has been detected 
also in G1 phase (Shen et al. 2004). This unscheduled expression may lead to substrate 
phosphorylation regardless of the cell cycle phase, causing uncontrolled cell cycle 
progression, and be one of the mechanisms in carcinogenesis. The mechanism leading to 
this unscheduled expression remains to be elucidated; it can be due to disturbances either 






regulate the G2-M transition by increasing and decreasing cyclin B1 level by binding to its 
promoter site (Innocente et al. 1999). Disturbances in p53 control of cyclin B1 level may 
thus be one of the mechanisms leading to cyclin B1 overexpression, induced cell division, 
and transformation to malignancy. High cyclin B1 expression has been detected in several 
malignancies (Murakami et al. 1999, Soria et al. 2000, Nozoe et al. 2002, Takeno et al. 
2002, Yoshida et al. 2004, Ikueworo et al. 2006). It has been associated with high tumor 
grade and advanced stage of disease as well as with poor prognosis in several cancers, 
including esophageal squamous cell (Murakami et al. 1999, Nozoe et al. 2002, Takeno et 
al. 2002), non-small cell lung (Soria et al. 2002, Yoshida et al. 2004), and renal cell 
cancers (Ikueworo et al. 2006). 
2.3.4 Cyclin B1 in breast cancer 
Cyclin B1 expression level is often high in breast cancer and has been shown to rise from 
benign and premalignant to advanced malignant breast l sions (Kawamoto et al. 1997). In 
breast cancer, the association of cyclin B1 with prognosis has thus far been evaluated in 
four rather small populations. In a study with 73 breast cancers, both nuclear and 
cytoplasmic expressions were independent predictors of poor relapse-free and overall 
survival (Winters et al. 2001). Cyclin B1 expression was not associated with tumor size, 
nodal status, grade, ER positivity, or p53 immunohistochemical expression. In a study 
with 332 T1-2 N-negative breast cancers (Kühling et al. 2003, Rudolph et al. 2003), high 
cyclin B1 expression was associated with relapse-fre  and overall survival in univariate 
analysis, but was not an independent prognostic factor in a multivariate analysis that 
included Ki67 as a covariate (Kühling et al. 2003). When 273 tumors treated with surgery 
and postoperative radiation only were analyzed, cyclin B1 was an independent predictor of 
poor overall survival among premenopausal but not pos menopausal patients (Rudolph et 
al. 2003). Tumors with high cyclin B1 expression were more often of high grade, ER- and 
PR-negative, and also had high Ki67, cyclin A, and cyclin E expression. In a small study 
with 56 invasive stage I-II cancers, cyclin B1 was not associated with prognosis (Peters et 
al. 2004). A recent study with 109 breast cancers showed an association between only 






2.3.5 Cyclin D1 
Cyclin D1-CDK4/6 complex is a critical regulator of G1/S transition through pRb 
phosphorylation and titration of p21 and p27 levels, as described earlier (Sherr 1996). The 
major function of cyclin D1 is to integrate stimuli from extracellular mitogenic factors, 
such as tyrosine kinases and hormones, with cell cyc e progression during the G1 phase 
(Kato et al. 1993). After mitogenic activation, cyclin D1/CDK4/6 complex begins pRb 
phosphorylation, but also sequesters CDK inhibitors, e.g. p27 and p21, thus relieving 
cyclin E/CDK2 complex of its inhibitory control. Estrogen directly targets cyclin D1, and 
cyclin D1/CDK 4/6 complex level rises shortly after estrogen stimulation (Doisneau-Sixou 
et al. 2003). pRb is an important substrate of cyclin D1/CDK4/6 complex; in cells lacking 
pRb, cyclin D1 is not required for cell cycle progression. Cyclin D1 seems to have CDK-
independent functions, too, which contribute to itsoncogenic actions (Arnold & 
Papanikolaou 2005). Cyclin D1 may activate estrogen receptor without estrogen, and thus, 
drive all the mitogenic effects of estrogen on breast cells (Neuman et al. 1997, Lamb et al. 
2000). 
2.3.6 Cyclin D1 in breast cancer 
Cyclin D1 is overexpressed in about 50% of breast cncers, partly due to CCND1 gene 
amplification and partly due to translational or posttranslational deregulation (Gillett et al. 
1994). CCND1 gene amplification occurs in about 15-20% of breast cancers. Cyclin D1 
overexpression has also been detected in ductal hyperplasia and ductal carcinoma in situ 
(DCIS), indicating that it may have a role in the evolution of early breast cancer (Wang et 
al. 1994). Breast cancers with high cyclin D1 expression are more frequently hormone 
receptor-positive than -negative. The association of cyclin D1 with tumor grade and 
proliferation is not fully understood; associations between high cyclin D1 levels and low-
grade tumor and low proliferation rate have been report d (van Dienst et al. 1997, Han et 
al. 2003, Hwang et al. 2003, Jirström et al. 2005), but not consistently in all studies 
(Michalides et al. 1996, Umekita et al. 2002, Reis-Filho et al. 2006). The relationship 
between cyclin D1 and HER2 overexpression also remains unclear. One study on 113 
primary breast cancers and breast cancer cell lines suggested that proliferation is increased 






does not seem to have an independent prognostic role in breast cancer; there are several 
studies that have been unable to show any association nd a few have even shown an 
association of high cyclin D1 with better prognosis (Michalides et al. 1996, van Dienst et 
al. 1997, Gillett et al. 1998, Umekita et al 2002, Reis-Filho et al. 2006, Elsheikh et al. 
2007). Instead of being a prognostic factor, cyclin D1 has been suggested to mediate 
tamoxifen resistance (Stendahl et al. 2004, Ahnström et al. 2005, Jirström et al. 2005). 
2.3.7 Cyclin E 
Cyclin E expression rises and cyclin E/CDK2 complex becomes released from CDK 
inhibitors p27, p21, and others at the G1/S transition as a result of activity of cyclin 
D1/CDK4/6. Activated E2F can induce cyclin E as well and creates a positive feedback 
loop that contributes to the irreversibility of the G1/S transition. Cyclin E/CDK2 carries 
on the inactivation of pRb later in G1 and enables further upregulation of genes needed for 
DNA replication (Sherr 1996). Cyclin E also facilitates the first events of the S phase. 
Cyclin E/CDK2 complex is capable of phosphorylating substrates besides pRb that 
mediate its proliferative actions, and cyclin E can ccelerate entry into S phase 
independently of pRb (Ohtsubo et al. 1995). One of these substrates is the p27 inhibitor, 
and cyclin E facilitates its own activation by phosphorylating p27. In normal cells, cyclin 
E becomes quickly degraded by multiple mechanisms, and during early G1 and G2/M 
phases its level and activity are low. 
Cyclin E overexpression can cause chromosomal instability, potentially by disturbing 
proper chromosome duplication and segregation (Spruck et al. 1999). Cyclin E 
overexpression is common in cancer. Amplification of its coding gene CCNE is unusual; 
instead, posttranslational deregulation seems to behe mechanism leading to high cyclin E 
expression (Keyomarsi et al. 1995). Further splicing of the CCNE transcript as well as 
posttranslational proteolytic cleavage of the cyclin E protein lead to the formation of low 
molecular weight (LMW) isoforms of cyclin E found in tumor tissues (Porter & 






2.3.8 Cyclin E in breast cancer 
Cyclin E expression has been shown to be often high in breast cancers with an aggressive 
tumor phenotype. High cyclin E expression correlates with hormone receptor negativity, 
high tumor grade, and large tumor size (Nielsen et al. 1996, Donnellan et al. 2001, 
Keyomarsi et al. 2002, Han et al. 2003, Rudolph et al. 2003, Lindahl et al. 2004). 
Furthermore, correlations between high cyclin E andhigh Ki67 count and younger age at 
diagnosis have been reported (Külhing et al. 2003, Lindahl et al. 2004, Berglund et al. 
2008). One study found that high cyclin E was more common among HER2-positive 
tumors (Potemski et al. 2006). Medullary histology has been described as more common 
among tumors with high than low cyclin E expression, suggesting cyclin E’s ability to 
modulate the infiltrative behavior of the tumor (Berglund et al. 2005). Tumors with high 
cyclin E have also been shown to have a specific p53 mutation spectrum, with mainly 
insertions and deletions and undetectable p53 expression (Lindahl et al. 2004). Most 
studies evaluating the prognostic role of cyclin E in breast cancer have revealed an 
association with poor prognosis (Nielsen et al. 1996, Keyomarsi et al. 2002, Han et al. 
2003, Kühling et al. 2003, Rudolph et al. 2003, Lindahl et al. 2004, Chappuis et al. 2005, 
Spruck et al. 2006). In some of these studies, an independent effect on poor prognosis in 
multivariate analysis could not be found. Some studies have suggested that the prognostic 
effect can only be seen when the LMW forms of cyclin E are measured. High cyclin E has 
also been speculated to predict endocrine therapy filure (Span et al. 2003, Akli et al. 
2004, Desmedt et al. 2006). One study consisting only f patients treated with adjuvant 
chemotherapy showed no adverse prognostic effect (Por er et al. 2006). A meta-analysis 
with 2534 patients, however, revealed that high cyclin E was associated with poor relapse-
free survival (RR 1.72, 95% CI 0.95-3.10) and with poor overall or breast cancer-specific 
survival (RR 2.86, 95% CI 1.85-4.41) also in multivariate analysis (Wang & Shao 2006). 










































cell cycle genes 
 
Figure 2 Simplified model of cell cycle G1 to S transition (adapted from Sherr & Roberts 
1999). 
2.3.9 Proliferation antigen Ki67 
Ki67 is a nuclear protein that is absent in quiescent cells, but universally expressed in 
proliferating tissues (van Dierendonck et al. 1989, Gerdes et al. 1991), and thus, can be 
used as a marker of cell proliferation. Ki67 level in cells rises during G1 and S phases and 
reaches its maximum during mitosis. Ki67 seems to have a critical role in cell division, but 
little is known about its exact function (Heidebrecht et al. 1996). While the prognostic role 
of Ki67 in early breast cancer has been unclear, a ecent meta-analysis suggests a 
significant association with poor disease-free and overall survival in univariate analysis 
(de Azambuja et al. 2007). Because multivariate prognostic analyses were not conducted, 
the independent prognostic value of Ki67 cannot be det rmined. Furthermore, uncertainty 
remains about the optimal cut-off values of Ki67 (Urruticoechea et al. 2005). A study 
investigating the optimal cut-off values of cyclin A and Ki67 in prognostic evaluation 
suggested the optimal cut-off value for identifying tumors with poor prognosis for Ki67 to 






2.4 Tissue microarray (TMA) technique 
In the tissue microarray (TMA) technique (Kononen et al. 1998), small cylinders 
(diameter 0.6 µm) from hundreds of separate tumors are punched and brought into a single 
recipient TMA block. Sections of these blocks can then be used in tumor marker analyses 
on a DNA, RNA, and protein level. This technique allows simultaneous staining and 
analysis of a large number of tumors, enabling rapid, large-scale investigations of new 
tumor markers. Since the TMA technique takes only small cylindrical specimens from the 
donor blocks, these donor blocks remain virtually undamaged and can be used for several 
studies. 
As only a small punch (0.6 µm) from each tumor is analyzed on TMA, a question has 
arisen of the representativeness of this minute tissue punch and the possible effect of 
tumor heterogeneity on results. Several studies have shown that although an individual 
result on TMA and on a corresponding large-section slide may differ, the correlations 
between histopathological features and prognostic implications are similar when large 
tumor materials are investigated (Kononen et al. 1998, Camp et al. 2000, Gillett et al. 
2000, Nocito et al. 2001, Torhorst et al. 2001). ER, P , and HER2 expression has been 
examined on breast cancer TMAs, and the results have been reliable (Kononen et al. 1998, 
Camp et al. 2000, Gillett et al. 2000, Torhorst et al. 2001). Expression of cell cycle 
regulators cyclin D1 and E also show similar results on TMA and on traditional large-
section slides (Richter et al. 2000, Han et al. 2003, Hedberg et al. 2003, Jirström et al. 
2003, Schraml et al. 2003, Stendahl et al. 2004). It has, however, been unclear how 
representative TMA is when studying markers with heterogenic expression in different 






3 AIMS OF THE STUDY 
This study aimed to bring new insights into the biological roles and clinical implications 
of cell cycle regulator protein cyclins in breast can er. Specific aims were to evaluate: 
1. the reliability and reproducibility of cyclin A immunohistochemical assessment on 
TMA compared with traditional histological slides 
2. cyclin D1, E, and B1 expression in familial breast cancer, focusing on differences in 
expression between tumors of sporadic, familial non-BRCA1/2, BRCA1-, and BRCA2-
positive breast cancer patients 
3. the role of cyclin D1 gene (CCND1) G870A polymorphism in breast cancer 
predisposition alone and in combination with estrogen metabolism enzyme COMT 
Met108/158Val polymorphism 
4. the associations of cyclin D1, E, and B1 expression with breast cancer phenotype, 






4 PATIENTS AND METHODS 
4.1 Patients 
4.1.1 Breast cancer TMAs (I, II, IV, V) 
The breast cancer TMAs consist of 1348 invasive breast tumors and constitute the material 
in Studies II, IV, and V. Of these tumors 884 are fom unselected patients of the 
Department of Oncology, Helsinki University Central Hospital, seen in 1997, 1998, and 
2000 (79% of all consecutive, newly diagnosed breast c ncer cases during the collection 
periods). The unselected series have been described in detail by Syrjäkoski et al. (2000) 
and Kilpivaara et al. (2005). Of the unselected tumors, 439 are from sporadic and 445 
from patients with one first-degree or two or more fi st- or second-degree relatives with 
breast or ovarian cancer. An additional 464 tumors from familial breast cancer patients 
were located by a systematic screening at the Department of Oncology, Helsinki 
University Central Hospital, or were ascertained through genetic counseling at the 
Department of Clinical Genetics (described by Eerola et al. 2000). Of all familial patients’ 
tumors, 453 are from patients with a strong positive family history (at least three first- or 
second-degree relatives with breast or ovarian cancer, including the proband), 341 from 
patients with two affected first-degree relatives (including the proband), 56 from BRCA1 
mutation carriers, and 59 from BRCA2 mutation carriers. The BRCA1 and BRCA2 
mutation screening of familial tumors has been described earlier in Vehmanen et al. 
(1997) and Vahteristo et al. (2001). 
In Study I, 200 tumors from the unselected series colle ted between 1997 and 1998 were 
randomly selected and cyclin A expression of these tumors was examined both on TMAs 
and on traditional large section histological slides. 
4.1.2 Characterization of tumors (I, II, IV, V) 
All cancer diagnoses were confirmed through the Finnish Cancer Registry. Noninvasive 
cancers were excluded. Information on tumor histology, grade, size, nodal status, distant 






considered positive for ER and PR if 10% or more of the cancer cells were stained. An 
expert breast cancer pathologist re-reviewed all tumors for tumor histology and grade 
(Eerola et al. 2005). Grading was performed according to Scarff-Bloom-Richardson 
(1957), modified by Elston and Ellis (1991). HER2 protein expression on TMAs was 
analyzed by immunohistochemical staining and gene amplification with chromogenic in 
situ hybridization (CISH), and p53 protein expression by immunohistochemical 
expression. The methods for HER2 analysis have beend scribed in detail by Tanner et al. 
(2000) and Lassus et al. (2004) and for p53 immunohist chemistry by Tommiska et al. 
(2005). 
4.1.3 Follow-up data (IV, V) 
Information on adjuvant treatment and distant metastases during the follow-up was 
collected from patient records. Information on death due to breast cancer or another reason 
came from the Finnish Cancer Registry. Survival wasanalyzed as metastasis-free survival 
(MFS); the time from the date of primary surgery to the date of radiological confirmed 
distant metastases, and as overall survival (OS); the time from the date of primary surgery 
to the date of death due to breast cancer. A total of 797 patients were accepted to survival 
analysis in Studies IV and V, including the unselected series and the familial patients 
ascertained within 6 months after diagnosis. The median follow-up time of these patients 
was 93 (2-516) months. The patients were treated according to standard guidelines at that 
time regarding adjuvant chemotherapy, radiotherapy, nd endocrine treatment. Of these 
797 patients, 796 (99.9%) underwent surgery, 691 (87%) adjuvant radiotherapy, 323 
(41%) adjuvant chemotherapy, and 359 (45%) adjuvant endocrine treatment. Of the 
patients who received adjuvant chemotherapy, 163 (50%) were treated with CMF 
(cyclophosphamide-methotrexate-5-fluorouracil), 102 (32%) with CEF 
(cyclophosphamide-epirubicin-5-fluorouracil), and 58 (18%) with some other 
chemotherapy regimen. Of all patients in the survival analysis, 127 (16%) relapsed with 







4.1.4 Breast cancer patients in Study III 
All Finnish breast cancer cases (n=728) were included in the unselected breast cancer 
series collected between 1997-1998 and 2000. Of these cases, 73% (n=534) were sporadic, 
with no family history of breast or ovarian cancer, and 27% (n=194) had at least one first-
degree relative with breast or ovarian cancer. The ag  range of these cases was 22-69 
years, the average age being 53.2 ± 9.34 years. 
The breast cancer cases from Ontario, Canada (n=1228), were identified through the 
Ontario Cancer Registry and recruited into the Ontario Familial Breast Cancer Registry 
(OFBCR). They were diagnosed with pathologically confirmed breast cancer between 
1996 and 1998. Of these cases, 73% represent women at increased risk of genetically 
related breast cancer (Ashkenazi Jewish background, diagnosed before age 36 years, 
previous ovarian or breast cancer diagnosis, one or more first- or two or more second-
degree relatives with breast or ovarian cancer, one r more second- or third-degree 
relatives with either breast cancer diagnosed before age 36 years, ovarian cancer 
diagnosed before age 61 years, multiple breast or breast and ovarian primaries, or male 
breast cancer, or three or more first-degree relativ s with any combination of breast, 
ovarian, colon, prostate, or pancreatic cancer or sarcoma, with at least one diagnosis 
before age 51 years) and 35.6% had one or more first-degree relatives with breast or 
ovarian cancers. The age range of these cases was 25-69 years, the average age being 48.8 
± 9.26 years. 
4.1.5 Population controls (III) 
The population controls in the Study III were collected from Finland and Ontario, Canada. 
The Finland population controls (n=687) comprised halthy females collected from the 
same geographical region as the cases. The age rangof the Finland controls was 21-65 
years, the average age being 47.1 ± 10.12 years. The Ontario population controls (n=719) 
were recruited from the OFBCR by calling randomly selected residential telephone 
numbers from across the province of Ontario and were frequency-matched to all female 
OFBCR cases by 5-year age group. The age range of the Ontario population controls was 







4.2.1 TMA construction (I, II, IV, V) 
Paraffin blocks from the patients’ primary tumors were collected. Hematoxylin and eosin 
sections were reviewed, and the most representative tumor areas were selected. These 
areas from each tumor were punched and placed on recipient paraffin blocks to produce 
TMAs consisting of four cores with diameter 0.6 µm (two cores from BRCA-positive 
tumors) for each tumor. Then 3- to 4-µm-thick sections were cut from array blocks and 
transferred to glass slides (Eerola et al. 2005). 
4.2.2 Immunohistochemistry (I, II, IV, V) 
Deparaffinization of the TMA samples was performed using xylene. The slides were 
rehydrated through graded alcohols to water. Cyclin A immunostaining was performed 
manually. Antigen retrieval was done using a pressure cooker for 5 min in 0.01 M citrate 
buffer, pH6.0. Primary antibody (mouse monoclonal, Novocastra Laboratories) was 
diluted 1:300 and incubated overnight. Staining was done using the avidin biotin 
peroxidase complex and amino-ethyl-carbazole (AEC) procedures (Wood & Warnke 
1981). Cyclin B1, D1, and E and Ki67 immunostainings were performed in an automated 
immunostainer (Ventana Medical Systems Inc.) using a diaminobenzidine (DAB) kit 
(Ventana). Antigen retrieval was done using an iView-kit. Cyclin E (BD Pharmingen) and 
cyclin D1 (Novocastra) were diluted 1:20, and cyclin B1 (Novocastra) 1:40. Ki67 (Mib-1, 
Dako cytomation) was diluted 1:100. 
The formalin-fixed paraffin-embedded tissue material f om the blocks of the 200 tumors 
in Study I was cut into 3- to 4-µm-thick sections ad deparaffinized. The immunostaining 
for cyclin A was performed similarly to the immunostaining of TMAs. 
4.2.3 Evaluation of immunoreactivity scores (I, II,  IV, V) 
Immunostainings on TMA slides were analyzed by at least one and sometimes two 
investigators. All scoring was done under the supervision of an experienced breast cancer 






both TMAs and traditional large-section histological slides by two investigators. For all 
immunostainings, the number of positive breast cancer cells was counted in one high-
power field (40X objective) in each of the four tissue cores on TMA. Only unequivocal 
nuclear staining was accepted as a positive reaction for cyclin A, cyclin D1, cyclin E, and 
Ki67. For cyclin B1, both nuclear and cytoplasmic reactions were accepted as positive. A 
minimum of 200 cells was counted in each tumor, except for cyclin B1 immunostaining, 
where a minimum of 500 cells was counted. The result was the proportion of all positive 
cells of the total number of breast cancer cells counted from the four biopsies. In Study I, 
the maximal and the average values of the four cores w re used in analyses, and in the 
large sections three randomly selected and one “hot-sp t” high-power field were 
evaluated. 
Most of the analyses were performed using cyclin and Ki67 results as continuous 
variables, but to better demonstrate some of the histopathological associations and 
prognostic effects, the results were dichotomized at mean values. In Study I, cyclin A was 
dichotomized at a cut-off value of 10% (Poikonen et al. 2005), and in Study V, cyclin B1 
was dichotomized at 5.6% (corresponding to the 7th decile). 
4.2.4 DNA extraction (III) 
A standard phenol-chloroform method was used to extract genomic DNA from peripheral 
blood leukocytes of the breast cancer patients and co trols. 
4.2.5 Molecular genotyping (III) 
The genotyping of the Finnish breast cancer and population control DNA specimens for 
COMT and CCND1 polymorphisms was done using Amplifluor fluorescent genotyping 
(K-Biosciences, Cambridge, UK) (Tommiska et al. 2005). The genotyping of the DNA 
samples from the Canadian breast cancer cases and controls was performed using TaqMan 
5’nuclease assay with the ABI PRISM 7900 HT Sequence Detection System (version 2.0) 
(Onay et al. 2006). A randomly selected 10% portion of the total study population was re-






4.2.6 Statistical methods 
Statistical software package SPSS version 13.0 for Windows (SPSS, Chicago, IL, USA) or 
SISA (http://home.clara.net/sisa/) was used for all analyses. Two-sided P-value of 0.05 
was considered to indicate statistical significance, unless otherwise stated. 
The reproducibility of the two readers’ results and the results achieved by two methods 
was evaluated with Kappa values. Correlations were assessed with either Mann-Whitney 
U-test (dichotomized variables) or Spearman’s rho correlation test (continuous variables). 
Logistic regression analysis (stepwise backwards logistic regression, 99%) was used in 
multivariate analysis of associations. Survival was analyzed with Cox regression analysis 
in univariate and multivariate models. Kaplan-Meier su vival curves were calculated. To 
determine the optimal cut-off value for separation f tumors with good versus poor 
prognosis, the material was divided into 10 deciles. The cut-off values corresponding to 
each decile limit were used to split the material into two parts. For each cut-off, the 
relative risk (RR) for survival with 95% confidence interval (CI) was calculated using the 
Cox regression analysis. 
The associations of SNPs with controls and cases were m asured by odds ratio (OR) and 
its corresponding 95% CI. The Trend Analysis Program (PEPI computer software 
package, Sagebrush Press, Salt Lake City state, USA) was applied to detect trends from 
SNP interactions. 
4.3 Ethics 
All studies were carried out with the informed conse t of patients and were approved by 
the Ethics committee of the Helsinki University Central Hospital and the Ministry of 







5.1 Cyclin A assessment on TMA (I) 
Because cyclin A expression is heterogeneous througout the tumor, we evaluated the 
reliability of cyclin A assessment on TMAs, where only small punches from each tumor 
are analyzed. Both maximum and average cyclin A counts were studied. Of 200 tumors 
investigated, the results of 14 tumors (7%) were missing on TMA, due to either loss of all 
punches during the staining or lack of tumor in the arrayed samples. The result of only one 
tumor was missing on large sections, due to unsuccesful staining. The median cyclin A 
count was 3.7% (range 0–34.4%) on TMA average values, 5.8% (0-52.9%) on TMA 
maximum values, 4.3% (0–32.1%) on large-section average values, and 9.0% (0–39.1%) 
on large-section maximum values. 
5.1.1 Agreement of two readers’ results 
The two readers’ results were concordant in 173 cases (96%) on TMA average values, in 
167 cases (92%) on TMA maximum values, in 174 cases (87%) on large-section average 
values, and in 180 cases (90%) on large-section maximum values. The mean difference 
between the two readers’ scoring and 95% limits of agreement were 0.1% (-4.8% – 
+5.1%) for TMA average values, 0.4% (-8.0% – +8.8%) for TMA maximum values, 0.4% 
(-4.4% – +5.1%) for large-section average values, and 1.0% (-7.5% – +9.5%) for large-
section maximum values. The kappa values evaluating the reproducibility of two readers’ 
results were 0.87 for TMA average value, 0.83 for TMA maximum value, 0.71 for large-
section average value, and 0.80 for large-section maxi um value. The mean number of 
nuclei counted (the mean of two readers’ results) was 661 in concordant tumors versus 
420 in discrepant tumors (P=0.002) for array averag values, 671 in concordant versus 410 
in discrepant tumors (P<0.0005) for array maximum values, 767 in concordant versus 465 
in discrepant tumors (P<0.0005) for large-section aver ge values, and 759 in concordant 






5.1.2 Agreement of cyclin A results on TMA and larg e sections 
TMA and large-section cyclin A results were compared using the median values of the 
two readers’ results. Of average values 171 (92%) were concordant, and of maximum 
values 152 (82%). The mean difference between the TMA and large-section scoring and 
95% limits of agreement were 0.4% (-6.9% – +7.6%) for average values and 2.0% (-8.7% 
– +12.6%) for maximum values. The kappa values were 0.75 for average values and 0.62 
for maximum values. The mean number of nuclei counted was 683 in concordant tumors 
and 308 in discrepant tumors for average values (P<0.0005). For maximum values, the 
mean number of cells counted in concordant tumors was 661 and in discrepant tumors 612 
(P=0.33). The associations of cyclin A with other histopathological factors and survival 
were similar in TMA average and maximum values as well as in large-section average and 
maximum values. High cyclin A expression was associated with ER negativity 
(P<0.0005), PR negativity (P<0.0005), and high grade (P<0.0005). High cyclin A was 
associated with poor MFS, but did not have a significant effect on OS. 






TMA average  0.529 <0.0005
TMA maximum  0.537 <0.0005
large-section average  0.555 <0.0005
large-section maximum  0.523 <0.0005
Nodal status
TMA average  -0.078 0.38
TMA maximum  -0.065 0.45
large-section average  -0.046 0.58
large-section maximum  -0.023 0.80
ER
TMA average  -0.417 <0.0005
TMA maximum  -0.414 <0.0005
large-section average  -0.453 <0.0005
large-section maximum  -0.459 <0.0005
PR
TMA average  -0.427 <0.0005
TMA maximum  -0.427 <0.0005
large-section average  -0.453 <0.0005






5.2 CCND1 G870A and COMT Met108/158Val polymorphism s (III) 
The series of 728 breast cancer cases from Finland and 1223 from Ontario, Canada, and 
687 population controls from Finland and 719 from Ontario were screened for CCND1 
G870A and COMT Met108/158Val polymorphisms. The frequ ncy of COMT high 
enzymatic activity allele (Val) was 0.45 in Finnish and 0.47 in Canadian control 
populations, and the frequency of CCND1 high enzymatic activity allele (A) was 0.46 in 
both control populations. No deviation from the Hardy-Weinberg equilibrium was 
detected. 
5.2.1 Association of COMT Met108/158Val polymorphis m with breast cancer 
risk 
The heterozygous medium enzymatic activity COMT MetVal genotype and the 
homozygous high enzymatic activity COMT ValVal genotype were associated with 
increased breast cancer risk in Canadian cases (OR 1.3, 95% CI 1.07-1.68 and OR 1.4, 
95% CI 1.07-1.81, respectively). Among Finnish cases, however, no significant 
association or increased trend for breast cancer risk with COMT MetVal or ValVal 
genotypes (OR 1.0, 95% CI 0.73-1.39) was found. 
A meta-analysis of thirteen studies with genotype data from 6809 cases and 6190 controls 
was carried out to assess the association of COMT Met108/158Val polymorphism with 
breast cancer risk. Overall fixed-effects for pooled OR were slightly increased, but not 
significant for MetMet versus ValVal genotype (OR 1.08, 95% CI 0.93–1.24, P=0.32). 
The genotype distribution of the control populations i  two studies deviated from the 
Hardy-Weinberg equilibrium. The meta-analysis was repeated after removing these two 
studies, after which a significant association with breast cancer risk for MetMet vs. ValVal 
genotype (OR 1.14, 95% CI 1.03-1.26, P=0.01) with no heterogeneity (MetMet vs. 






5.2.2 Association of CCND1 G870A polymorphism with breast cancer risk 
The high enzymatic activity CCND1 AA genotype was as ociated with increased breast 
cancer risk in both Canadian (OR 1.3, 95% CI 1.00-1.69) and Finnish samples (OR 1.4, 
95% CI 1.01-1.84). 
5.2.3 Characteristics of tumors from patients with CCND1 AA genotype 
Characteristics of the tumors from 728 Finnish cases w re studied. Tumors of patients 
with AA, AG, or GG genotypes were very similar, and the AA genotype had no 
significant association with tumor TNM status, grade, histology, hormone receptor status, 
HER2, or p53 or Ki67 count. Nor did the CCND1 G870A genotype and cyclin D1 
expression correlate. 
5.2.4 Combined effect of CCND1 G870A and COMT  Met108/158Val 
polymorphisms 
The association of the combined CCND1 and COMT genotypes with breast cancer 
predisposition was also evaluated. The low enzymatic activity genotype combination of 
CCND1 and COMT (CCND1 GG/COMT MetMet) was taken as  reference and 
compared with the medium- (heterozygote combinations) and high-activity (CCND1 
AA/COMT MetVal and CCND1 AA/COMT ValVal) combinations. In the Canadian 
series, the heterozygote and the high-activity genotype combinations showed significant 
associations with increased breast cancer risk (OR 1.66, 95% CI 1.18-2.33 for medium- 
and OR 2.22, 95% CI 1.49-3.28 for high-activity combination). In the Finnish series, the 
high-activity genotype combinations were also signif cantly associated with increased 
breast cancer risk (OR 1.73, 95% CI 1.08-2.78). The medium-activity combinations in the 
Finnish sample showed a trend of increased breast cancer risk (OR 1.21, 95% CI 0.81-
1.83), but did not reach statistical significance. The COMT and CCND1 genotype 
interactions were also investigated in subgroups defined by age, familial status, and ER 
status; the associations were, however, similar to those in the overall analysis. 
The Canadian study was designed to reach 80% power in d tecting an OR of about 2.1 for 






using a two-sided test. Although the Finnish study included less cases and controls, it 
achieved almost the same power, assuming the direction of the effect is known and a one-
sided test can be used; both assumptions are justified in a replication study. 
5.3 Cyclin D1 and E expression (II, IV) 
The TMAs with 1348 invasive breast cancers were stained with cyclin D1 and E 
antibodies to investigate the associations of these markers with other tumor characteristics, 
familial background, and prognosis. The cyclin D1 result was obtained from 1187 tumors 
(88.1%) and the cyclin E results from 1180 tumors (87.5%). In the remaining cases, the 
biopsy did not contain enough tumor cells to be evaluated or the staining was 
unsuccessful. The median cyclin D1 count was 9.0% (range 0-81%) and the median cyclin 
E count 6.5% (range 0-68%). The tumors with expression above the mean expression of 
all tumors (6.8% for cyclin E and 9.1% for cyclin E) were considered high-expression 
tumors (positive) and those below the mean expression low-expression tumors (negative). 
5.3.1 Cyclin D1 and E expression among tumors of BR CA1 carriers 
Of BRCA1 tumors, 88% had high cyclin E expression and 84% had low cyclin D1 
expression. High cyclin E and low cyclin D1 count were significantly more common 
among BRCA1 than among familial non-BRCA1/2 (P<0.005) or sporadic tumors 
(P<0.0005). Other factors differentiating BRCA1 tumors from familial non-BRCA1/2 
tumors or sporadic tumors in univariate analysis were high tumor grade, younger age at 
diagnosis, and higher frequency of ER-, PR-, and HER2-negative, p53- and Ki67-positive 
tumors, and tumors with medullar histology. BRCA1 tumors also more frequently had 
negative nodal status than sporadic tumors. A multivariate model taking into account all 
factors significant in univariate analysis was constructed. The independent differentiating 
factors between BRCA1 and familial non-BRCA1/2 tumors were high cyclin E and low 
cyclin D1 expression, HER2 and ER negativity, and younger age at diagnosis. The factors 
distinguishing BRCA1 from sporadic tumors in multivariate analysis were ER and HER2 
negativity and younger age at diagnosis. High cyclin E and low cyclin D1 expression 






Table 5 Logistic regression analysis (first and final step) of BRCA1–associated breast cancer 
features in comparison with familial non-BRCA1/2 tumors and sporadic tumors. 
A. familial non-BRCA1/2 tumors B. sporadic tumors
Feature OR (95% CI) P-value Feature OR (95% CI) P-value
First step: First step:
HER2 neg 2.17 E+08* 0.997* HER2 neg 2.15 E+08* 0.997*
Cyclin E pos 5.36 (1.47-19.61) 0.01 Cyclin E pos 2.33 (0.62-8.71) 0.21
Cyclin D1 neg 4.63 (1.35-15.85) 0.02 Cyclin D1 neg 2.83 (0.78-10.31) 0.11
ER neg 3.14 (0.66-14.96) 0.15 ER neg 6.85 (1.19-39.26) 0.03
 Age <50 years 3.28 (1.25-8.63) 0.02  Age <50 years 4.53 (1.64-12.47) 0.003
P53 pos 2.45 (0.82-7.34) 0.11 P53 pos 1.22 (0.43-3.50) 0.71
PR neg 1.71 (0.35-8.32) 0.51 PR neg 2.20 (0.45-10.70) 0.33
Grade 3 0.73 (0.21-2.57) 0.62 Grade 3 1.97 (0.52-7.54) 0.32
Nodal status neg 1.40 (0.54-3.62) 0.49
Final step after stepwise regression: Final step after stepwise regression:
HER2 2.19 E+08* 0.997* HER2 neg 2.55 E+08* 0.997*
Cyclin E pos 5.58 (1.69-13.67) 0.01 ER neg 15.33 (6.06-38.75) <0.0005
ER neg 3.81 (1.35-10.76) 0.01  Age <50 years 4.40 (1.76-11.00) 0.002
Cyclin D1 neg 4.36 (1.33-14.22) 0.02
 Age <50 years 2.99 (1.17-7.65) 0.02
* All BRCA1 and BRCA2 tumors with HER2 result in this study were HER2 negative.  
Prevalence of combined phenotypes defined by the ind pendent differentiating factors 
(high cyclin E expression, low cyclin D1 expression, younger age at diagnosis, ER, and 
HER2 negativity) were further compared between mutation-positive and familial 
mutation-negative tumors to evaluate predictive value of these markers for BRCA1 
mutation. Including both high cyclin E and low cyclin D1 expression increased the OR of 
BRCA1 mutation to 27.82 and high cyclin E to 28.85, as compared with an OR of 19.12 
for traditional markers ER, HER2, and age at diagnosis alone. 
Table 6 Prevalence of combined immunotypes by ER, HER2, age at diagnosis, and cyclin E 
and D1 expression in BRCA1 and BRCA1 mutation-negative (BRCA2 and non-








neg 22 (75.9%) 84 (23.7%) 10.10 (4.17-24.48)
neg neg 22 (75.9%) 68 (19.2%) 13.22 (5.42-32.21)
neg neg <50 years 19 (65.5%) 32 (9.0%) 19.12 (8.19-44.62)
neg neg <50 years neg 17 (58.6%) 23 (6.5%) 20.39 (8.70-47.76)
neg neg <50 years pos 18 (62.1%) 19 (5.4%) 28.85 (11.95-69.63)
neg neg <50 years neg pos 16 (55.2%) 15 (4.2%) 27.82 (11.35-68.15)  
5.3.2 Cyclin D1 and E expression among tumors of BR CA2 carriers 
High cyclin E expression was seen in 58% and low cyclin D1 in 69% of BRCA2 tumors. 






BRCA1/2 (P=0.01) and low cyclin D1 significantly more common among BRCA2 than 
familial non-BRCA1/2 (P=0.002) or sporadic (P=0.009) tumors. Other factors 
differentiating BRCA2 tumors from familial non-BRCA1/2 and sporadic tumors in 
univariate analysis were negative ER, PR, and HER2 status and younger age at diagnosis. 
BRCA2 tumors were also more frequently N-, M-, and Ki67-positive than familial non-
BRCA1/2 tumors and more often of lobular histology than sporadic tumors. In 
multivariate analysis, the independent factors differentiating BRCA2 tumors from familial 
non-BRCA1/2 tumors were high cyclin E and low cyclin D1 expression, HER2 negativity, 
younger age at diagnosis, and negative nodal status. In comparison with sporadic tumors, 
only younger age at diagnosis and negative PR and HER2 status were independent 
differentiating factors. 
Table 7 Logistic regression analysis (first and final step) of BRCA2–associated breast cancer 
features in comparison with familial non-BRCA1/2 tumors and sporadic tumors. 
A. familial non-BRCA1/2 tumors B. sporadic tumors
Feature OR (95% CI) P-value Feature OR (95% CI) P-value
First step: First step:
Nodal status neg 0.39 (0.16-0.95) 0.04 ER neg 0.93 (0.28-3.13) 0.90
M neg 0.36 (0.05-2.36) 0.28 PR neg 2.09 (0.78-5.64) 0.15
PR neg 1.41 (0.54-3.69) 0.48 HER2 neg 2.29 E+10* 0.997*
HER2 neg 2.13 E+08* 0.998* Age <50 years 5.35 (2.38-12.02) <0.0005
Age <50 years 3.83 (1.48-9.91) 0.01 High cyclin E 1.12 (0.27-4.68) 0.88
High cyclin E 4.04 (1.49-10.93) 0.006 Low cyclin D1 1.34 (0.33-5.49) 0.69
Low cyclin D1 2.16 (0.83-5.61) 0.11
Final step after stepwise regression: Final step after stepwise regression:
HER2 neg 2.13 E+08* 0.998* HER2 neg 2.29 E+10* 0.997*
Age <50 years 3.75 (1.50-9.39) 0.01 PR neg 2.63 (1.23-5.63) 0.01
High cyclin E 3.69 (1.41-9.20) 0.007 Age <50 years 6.01 (2.72-13.29) <0.0005
Low cyclin D1 2.26 (0.93-5.54) 0.07
Nodal status neg 0.38 (0.16-0.89) 0.03
* All BRCA1 and BRCA2 tumors with HER2 result in this study were HER2 negative.  
5.3.3 Cyclin D1 and E expression among tumors of fa milial non-BRCA1/2 
patients 
Of familial non-BRCA1/2 tumors, 38% had high cyclin E and 45% low cyclin D1 
expression. As mentioned above, in univariate analysis, the frequency of tumors with high 
cyclin E expression was significantly lower than among BRCA1, BRCA2, or sporadic 
tumors (P<0.0005). The number of tumors with low cyclin D1 was significantly less than 






sporadic tumors (P=0.05). In univariate analysis, the other features differentiating familial 
non-BRCA1/2 from sporadic tumors were negative Ki67, N, and M status. In multivariate 
analysis, the only independent factors differentiating familial non-BRCA1/2 tumors from 
sporadic ones were low cyclin E expression and negative nodal status. Cyclin E and D1 
expression among families with two affected cases wa similar to that among sporadic 
tumors. 
Table 8 Logistic regression analysis (first and final step) of breast cancer features of familial 
non-BRCA1/2 patients in comparison with breast cancers of sporadic patients. 
Feature OR (95% CI) P-value
First step:
Nodal status neg 1.38 (1.01-1.86) 0.04
M neg 1.42 (0.60-3.73) 0.42
High cyclin E 0.49 (0.32-0.73) 0.001
Low cyclin D1 0.78 (0.51-1.17) 0.22
High cyclin E 0.56 (0.42-0.75) <0.0005
Nodal status neg 1.40 (1.04-1.89) 0.03
Final step after stepwise regression:
 
 









Frequency of high cyclin E tumors (n, %) 37 (88.1%) 26 (57.8%) 144 (38.4%) 215 (54.3%)
OR, 95% CI, P-value compared with 11.87 (4.56-30.70) 2.20 (1.17-4.11) - 1.91 (1.43-2.54)
familial non BRCA1/2 tumors <0.00005 0.01 - <0.00005
OR, 95% CI, P-value compared with 6.23 (2.40-16.18) 1.15 (0.62-2.15) 0.52 (0.39-0.70) -
sporadic tumors <0.00005 0.66 <0.00005 -
Frequency of low cyclin D1 tumors (n, %) 37 (84.1%) 33 (68.8%) 167 (45.3%) 197 (48.9%)
OR, 95% CI, P-value compared with 6.39 (2.78-14.71) 2.66 (1.40-5.07) - 1.16 (0.87-1.54)
familial non BRCA1/2 tumors <0.00005 0.002 - 0.31
OR, 95% CI, P-value compared with 5.53 (2.41-12.69) 2.30 (1.21-4.37) 0.86 (0.65-1.15) -
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Figure 3 Percentage of tumors with high cyclin E, low cyclin D1, and high cyclin E/low cyclin 
D1 expression among familial non-BRCA1/2, BRCA1, BRCA2, and sporadic tumors. 
5.3.4 Associations of cyclin D1 with other tumor ch aracteristics and survival 
High cyclin D1 expression correlated with low tumor grade (P=0.01), positive nodal status 
(P=0.02), ER (P<0.0005) and PR (P<0.0005) positivity, and negative p53 
immunohistochemistry (P<0.0005). Among ER-negative tumors, high cyclin D1 was 
associated with low grade (P=0.08) and low Ki67 expr ssion (P=0.01), but among ER-
positive tumors, with high grade (P<0.0005), high Ki67 (P<0.0005), and high cyclin A 
(P<0.0005) expression. Of ER-positive grade 3 tumors, 67% had high cyclin D1 
expression, while only 21% of ER-negative grade 3 tumors showed high expression. The 
correlations between cyclin D1 and grade as well as Ki67 expression were similar among 
HER2-positive and -negative cases irrespective of ER status. When all tumors were 






among ER-positive cases they had a positive (P<0.0005) and among ER-negative cases a 
negative (P=0.004) correlation. The frequencies of ductal and lobular histology were not 
related to cyclin D1 expression, but medullar histology was more common among tumors 
with low than high cyclin D1 (P=0.007). Cyclin D1 expression was not associated with 
survival among all patients, but showed a trend towards poor MFS among ER-positive 
patients not given adjuvant chemotherapy (chemotherapy-naïve patients) (RR 1.74, 95% 
CI 0.93-3.24, P=0.08). 
5.3.5 Associations of cyclin E with other tumor cha racteristics and survival 
High cyclin E expression correlated with high grade (P<0.0005), large tumor size 
(P=0.009), ER (P<0.0005) and PR (P<0.0005) negativity, HER2 (P<0.0005) and p53 
(P<0.0005) positivity, high Ki67 (P<0.0005) and high cyclin A (P<0.0005) expression, 
and younger age at diagnosis (P<0.0005). All cyclin E correlations, except the correlation 
with cyclin D1 expression, as indicated above, were similar among ER-positive and -
negative tumors. Ductal and medullar histology were more common among tumors with 
high than low cyclin E expression (P<0.0005 and P=0.00 8, respectively), but lobular 
histology was seen more frequently in tumors with low cyclin E (P<0.0005). High cyclin 
E expression correlated with poor MFS in univariate (RR 1.77, 95% CI 1.21-2.61, 
P=0.003) and multivariate (RR 1.76, 95% CI 1.17-2.64, P=0.006) analyses and with poor 
OS in univariate analysis (RR 1.62, 95% CI 1.05-2.52, P=0.03), but not in a multivariate 
model including tumor size, nodal status, grade, ER, P , and HER2 status (RR 1.01, 95% 
CI 0.91-2.34, P=0.41). Hormone receptor status, chemotherapy, or endocrine treatment did 






Table 10 Correlation of cyclin D1 with other tumor characteristics. 
A. Among all tumors
Variable Correlation coefficient 95% CI P-value
T  -0.120  -0.081 - 0.035 0.43*
N 0.070 0.013 - 0.127 0.02**
M 0.021  -0.037 - 0.079 0.49**
Grade***  -0.074  -0.131 - -0.017 0.01*
ER 0.373 0.323 - 0.422 <0.00005**
PR 0.297 0.243 - 0.350 <0.00005**
HER2 0.043  -0.015 - 0.101 0.15**
Ki67***  -0.039  -0.096 - 0.018 0.18*
Cyclin A*** 0.031  -0.027 - 0.089 0.30*
p53  -0.170  -0.226 - -0.113 <0.00005*
Age at onset 0.011  -0.046 - 0.068 0.69*
Cyclin E*** 0.000  -0.057 - 0.057 0.99*
B. Among ER-positive tumors
Variable Correlation coefficient 95% CI P-value
T 0.040  -0.027 - 0.107 0.24*
N 0.062  -0.006 - 0.127 0.07**
M 0.036  -0.032 - 0.103 0.30**
Grade*** 0.151 0.085 - 0.216 <0.0005*
PR 0.068 0.001 - 0.134 0.05**
HER2 0.073 0.005 - 0.140 0.04**
Ki67*** 0.156 0.089 - 0.221 <0.0005*
Cyclin A*** 0.261 0.197 - 0.323 <0.0005*
p53  -0.027  -0.095 - 0.041 0.43*
Age at onset  -0.042  -0.109 - 0.025 0.22*
Cyclin E*** 0.231 0.166 - -0.294 <0.0005*
C. Among ER-negative tumors
Variable Correlation coefficient 95% CI P-value
T  -0.02  -0.142 - 0.103 0.74*
N 0.107  -0.015 - 0.226 0.09**
M 0.026  -0.097 - 0.148 0.68**
Grade***  -0.109  -0.228 - 0.014 0.08*
PR 0.130 0.009 - 0.247 0.04**
HER2 0.192 0.067 - 0.311 0.003**
Ki67***  -0.155  -0.273 - -0.033 0.01*
Cyclin A***  -0.002  -0.125 - 0.121 0.97*
p53  -0.076  -0.198 - 0.048 0.23*
Age at onset 0.036  -0.086 - 0.157 0.56*
Cyclin E***  -0.178  -0.294 - -0.056 0.004*
* Spearman's Rho correlation test
** Mann-Whitney-U test
*** correlation is different among all tumors and among ER-positive 






Table 11 Correlation of cyclin E with other tumor characteristics. 
A. Among all tumors
Variable Correlation coefficient 95% CI P-value
T 0.077 0.019 - 0.134 0.009*
N  -0.004  -0.062 - 0.054 0.88**
M  -0.011  -0.069 - 0.047 0.71**
Grade 0.391 0.341 - 0.439 <0.0005*
ER  -0.348  -0.399 - -0.295 <0.0005**
PR  -0.288  -0.341 - -0.233 <0.0005**
HER2 0.176 0.119 - 0.232 <0.0005**
Ki67 0.389 0.339 - 0.437 <0.0005*
Cyclin A 0.402 0.352 - 0.449 <0.0005*
p53 0.242 0.186 - 0.296 <0.0005*
Age at onset  -0.146  -0.201 - -0.090 <0.0005*
Cyclin D1*** 0.000  -0.057 - 0.057 0.99*
B. Among ER-positive tumors
Variable Correlation coefficient 95% CI P-value
T 0.031  -0.037 - 0.098 0.37*
N 0.026  -0.042 - 0.094 0.45**
M  -0.025  -0.093 - 0.044 0.48**
Grade 0.247 0.183 - 0.309 <0.0005*
PR  -0.059  -0.126 - 0.008 0.09**
HER2 0.141 0.074 - 0.207 <0.0005**
Ki67 0.259 0.195 - 0.321 <0.0005*
Cyclin A 0.261 0.197 - 0.323 <0.0005*
p53 0.137 0.069 - 0.203 <0.0005*
Age at onset  -0.114  -0.180 - -0.047 0.001*
Cyclin D1*** 0.231 0.166 - 0.294 <0.0005*
C. Among ER-negative tumors
Variable Correlation coefficient 95% CI P-value
T 0.053  -0.070 - 0.175 0.40*
N  -0.055  -0.176 - 0.068 0.38**
M 0.003  -0.120 - 0.126 0.96**
Grade 0.372 0.261 - 0.473 <0.0005*
PR  -0.191  -0.305 - -0.071 0.002**
HER2 0.082  -0.044 - 0.206 0.200**
Ki67 0.396 0.287 - 0.495 <0.0005*
Cyclin A 0.423 0.317 - 0.519 <0.0005*
p53 0.116  -0.007 - 0.236 0.06*
Age at onset  -0.088  -0.207 - 0.034 0.156*
Cyclin D1***  -0.178  -0.294 - -0.056 0.004*
* Spearman's Rho correlation test
** Mann-Whitney-U test
*** correlation is different among all tumors and among ER-positive 






5.4 Cyclin B1 expression in breast cancer (V) 
Cyclin B1 expression was studied in the 1348 invasive breast cancers on TMAs. The 
staining was successful for 1100 tumors (81.4%). The median cyclin B1 value was 5.0% 
(range 0-72%). 
5.4.1 Cyclin B1 and other tumor characteristics 
High cyclin B1 expression was associated with large tumor size (P<0.0005), positive 
nodal status (P=0.008), high grade (P<0.0005), negative ER (P<0.0005) and PR 
(P<0.0005) status, positive p53 (P<0.0005), Ki67 (P<0.0005) and HER2 (P<0.0005) 
status, high cyclin A (P<0.0005) and cyclin E (P<0.0005) expression, and young age at 
disease onset (P<0.0005). Ductal and medullar histology were significantly more common 
among tumors with high than low cyclin B1 expression (P<0.0005 and P=0.0008, 
respectively), and lobular histology among tumors with low cyclin B1 (P<0.0005). 
Tumors with the highest cyclin B1 expression (above 10%) were more frequent among 
BRCA1 than sporadic (OR 2.8, 95% CI 1.4-5.6, P=0.003) or familial BRCA1/2 mutation-
negative (OR 4.8, 95% CI 2.3-9.9, P <0.0005) patients. Cyclin B1 expression among 
BRCA2 tumors did not significantly differ from expression among sporadic (OR 1.26, 
95% CI 0.55-2.87, P=0.58) or familial non-BRCA1/2 tumors (OR 2.16, 95% CI 0.93-5.01, 
P=0.07). 
5.4.2 Cyclin B1 expression and survival 
High cyclin B1 expression had a significant association with poor MFS (OR 2.48, 95% CI 
1.72-3.57, P<0.0005) and poor OS (OR 2.58, 95% CI 1.82-3.90, P<0.0005) in univariate 
analysis. The associations with poor MFS and OS were stronger among chemotherapy-
naïve patients (OR 3.51, 95% CI 2.05-6.01, P<0.0005 and OR 3.74, 95% CI 1.96-7.12, 
P<0.0005, respectively). Among the subgroup of patients that had received adjuvant 
chemotherapy, the association with poor MFS was weaker (OR 1.58, 95% CI 0.96-2.60, 
P=0.07) and no significant association with OS was found (OR 1.56, 95% CI 0.87-2.80, 
P=0.13). For survival analyses, cyclin B1 was dichotomized at the 7th decile 






value for proliferation markers is around the 7th decile. This corresponds to the proportion 
of grade 3 tumors in our material. 
A multivariate model including the TNM status, tumor grade, ER, PR, Ki67, p53, and 
HER2 status was constructed to analyze the independnt impact of cyclin B1 expression 
on prognosis. When all patients were analyzed, cyclin B1 had a significant independent 
association with poor MFS (OR 1.68, 95% CI 1.02-2.74, P=0.04) and a trend towards poor 
OS (OR 1.83, 95% CI 0.99-3.40, P=0.05). Among chemotherapy-naïve patients, the 
associations were stronger also in multivariate analysis. With tumor size and nodal status, 
cyclin B1 was the only factor independently predicting poor MFS (OR 2.31, 95% CI 1.17-
4.59, P=0.016) and OS (OR 1.79, 95% CI 1.28-4.14, P=0.04). 
Survival analyses were also assessed separately among subgroups divided by age at 
diagnosis or ER status, but the results remained similar. 















































Figure 4 Kaplan-Meier curves showing metastasis-free survival for cyclin B1 dichotomized at 







Table 12 Cyclin B1 expression (dichotomized at a cut-off of 5.6%) and survival in 
multivariable analysis (Cox regression analysis). 
A. Overall survival
All patients (n=797) RR 95% CI P-value
Nodal status 4.17 2.33-7.49 <0.0005
PR 1.99 1.10-3.61 0.02
HER2 1.91 1.15-3.18 0.01
Tumor size 1.87 1.47-2.37 <0.0005
Grade 1.79 1.14-2.79 0.01
Cyclin B 1.83 0.99-3.40 0.05
P53 1.15 0.91-1.47 0.25
Ki67 1.08 0.62-1.25 0.28
ER 0.89 0.45-1.76 0.74
Chemotherapy-naïve patients (n=473) RR 95% CI P-value
Nodal status 3.41 1.55-7.49 0.002
Tumor size 2.87 1.95-4.22 <0.0005
Cyclin B1 1.80 1.28-4.14 0.04
HER2 2.03 0.82-5.02 0.126
Ki67 1.79 0.82-3.79 0.20
PR 1.75 0.73-4.17 0.21
ER 1.70 0.52-5.55 0.38
Grade 1.43 0.78-2.63 0.25
P53 1.15 0.74-1.80 0.54
B. Metastasis-free survival
All patients (n=797) RR 95% CI P-value
Nodal status 2.97 1.87-4.67 <0.0005
Cyclin B1 1.68 1.02-2.74 0.04
Tumor size 1.64 1.33-2.03 <0.0005
Grade 1.63 1.14-2.32 0.008
HER2 1.46 0.92-2.31 0.11
PR 1.39 0.84-2.31 0.20
Ki67 1.26 0.67-1.52 0.26
P53 1.14 0.92-1.41 0.23
ER 0.81 0.45-1.47 0.49
Chemotherapy-naïve patients (n=473) RR 95% CI P-value
Nodal status 2.76 1.48-5.13 0.001
Cyclin B1 2.31 1.17-4.59 0.02
Tumor size 1.91 1.35-2.72 <0.0005
Grade 1.44 0.90-2.32 0.13
Ki67 1.39 0.82-1.65 0.35
PR 1.27 0.60-2.67 0.53
ER 1.10 0.36-3.36 0.87
HER2 1.10 0.46-2.63 0.82







6.1 Cyclin A expression can be reliably assessed on  TMA (I) 
The TMA technique allows a large number of tumors t be analyzed simultaneously, thus 
enabling relatively rapid screening of multiple markers. Cyclin A shows varying 
expression in different parts of the tumor. When this study was started, no cyclin A 
analyses on TMA had yet been published. Cyclin A expr ssion in Study I was investigated 
on TMA and on traditional large sections of 200 breast cancers. The agreement between 
these two methods was good, as was the reproducibility of the results by two independent 
readers. 
The kappa values describing the agreement of two readers’ results were 0.87 for TMA 
average, 0.83 for TMA maximum, 0.71 for large-section average, and 0.80 for large-
section maximum values. Kappa values from 0.61 to 0.80 are considered to reflect good 
agreement and those from 0.81 to 1.00 very good agreement (Altman 1991). Thus, the 
reproducibility of cyclin A assessment for the two readers in this study was good or even 
very good in both large sections and TMAs. Discrepant findings were associated with a 
low number of counted nuclei, thus a large number of cells counted seemed to improve 
reproducibility. The agreement between cyclin A asses ment on TMAs and large slides 
using the mean results of the two readers was good for both mean and maximum values. 
For average values, the agreement was better when the umber of cells counted increased. 
The agreement was moderately weaker for maximum than for average values. This can be 
explained by the method used in counting cells; on TMA one randomly selected high-
power field was counted on each punch, but on large sections we searched one “hot-spot” 
high-power field and selected the other three randomly. The agreement between TMA and 
large-section results for cyclin A in this study was similar to that reported for cyclins E 
and D1 in breast cancer (Han et al. 2003) and for Ki67 in bladder cancer (Nocito et al. 
2001). 
All histological and prognostic correlations were similar on TMA and large sections. The 
associations of high cyclin A with ER and PR negativity as well as with high grade are in 
line with earlier studies (Michalides et al. 2002, Michels et al. 2003). High cyclin A 






not an independent prognostic factor for overall survival. The results suggest that relative 
risks for overall and metastasis-free survival can be evaluated on TMA as reliably as on 
large sections. In conclusion, Study I showed that TMA can reliably be used in cyclin A 
immunohistochemical assessment of breast cancer. 
6.2 Cyclin expression in familial breast cancer (II , V) 
6.2.1 Familial BRCA1/2-negative breast cancers show  low cyclin E and high 
D1 expression (II) 
In Study II, we investigated the tumor phenotype of familial non-BRCA1/2 breast cancers, 
focusing on cyclin E and D1 expression, which among this patient group had not been 
investigated earlier. Moreover, we aimed to find tumor characteristics distinguishing 
familial mutation-negative cancers from BRCA1/2 positive and sporadic cancers. 
Most of the BRCA1 tumors had high cyclin E (88%) and low cyclin D1 (84%) expression. 
This is in concordance with earlier immunohistochemical studies (Osin et al. 1998, Armes 
et al. 1999, Vaziri et al. 2001) and cDNA studies showing that high cyclin E expression 
characterizes the basal-like breast cancer subtype, which is the most frequent cancer type 
in BRCA1 mutation carriers (Hedenfalk et al. 2001, Sorlie et al. 2003, Foulkes et al. 
2004). High cyclin E and low cyclin D1 expression were strong predictors of BRCA1 
mutation also when comparing BRCA1 tumors with familial non-BRCA1/2 cases in 
multivariate analysis. Between BRCA1 and sporadic tumors, however, the only 
independent differentiating factors were ER, HER2, and age at diagnosis. 
Of BRCA2 tumors, 58% had high cyclin E and 69% low cyclin D1 expression. High 
cyclin E and low cyclin D1 expression were also independent predictors of a BRCA2 
mutation in multivariate analysis when compared with familial non-BRCA1/2 tumors, but 
did not differentiate BRCA2 tumors from sporadic ones. Our data suggest cyclin E and D1 
expression can be used as a novel marker for predicting both BRCA1 and BRCA2 
mutation among familial breast cancer cases. This conclusion has not been reported 






mutation among breast cancer families is of high clinical importance, as patients are 
usually referred for genetic counseling and testing based on a family history of cancer. 
Another important new finding of Study II was that familial non-BRCA1/2 tumors 
differed significantly from sporadic breast tumors by having significantly lower cyclin E 
expression. Higher cyclin D1 expression differentiated these tumors from BRCA1- and 
BRCA2-associated tumors. Cyclin E and D1 were independent factors characterizing 
familial non-BRCA1/2 tumors in multivariate analysis as well. Similarities in cyclin E and 
D1 expression that reflect crucial events in cell cycle control and tumorigenesis among 
BRCA1 and BRCA2 tumors probably also reflect similarities in the functional roles of 
these two tumor suppressor genes in DNA repair, transcriptional regulation in response to 
DNA damage, and breast cancer predisposition (Yoshida & Miki 2004). The significantly 
different expression of cyclin E and D1 among familial non-BRCA1/2 tumors compared 
with both BRCA-associated and sporadic tumors may indicate that at least part of this 
group has unique biological characteristics and a genetic background that distinguishes it 
from both BRCA1 and BRCA2 tumors as well as from sporadic tumors. Whatever genetic 
change underlies these characteristics, it does not eem to involve the BRCA1 or BRCA2 
pathways since results for cyclin E and D1 expression in familial non-BRCA1/2 patients 
are opposite to those in BRCA-mutation carriers. 
6.2.2 BRCA1-related tumors have high cyclin B1 expr ession (V) 
In Study V, we investigated cyclin B1 expression in breast cancer. BRCA1 tumors 
significantly more often had high cyclin B1 (above 10%) expression than sporadic or 
familial non-BRCA1/2 tumors. To our knowledge, cyclin B1 expression among breast 
cancers of BRCA1 carriers has not been studied earlier, but this finding is in line with 
other characteristics of BRCA1-related cancers, e.g. high proliferation and grade. Cyclin 
B1 expression did not significantly differentiate can ers of BRCA2 carriers from sporadic 
or familial non-BRCA1/2 cancers, although high cyclin B1 seems somewhat more 






6.3 CCND1 G870A and COMT Met108/158Val high enzymat ic 
activity alleles increase breast cancer risk (III) 
In Study II, cyclin D1 and E expression was found to characterize breast cancers of 
familial non-BRCA1/2 patients as compared with mutation-positive and sporadic patients. 
In Study III, we furthermore wanted to study the contribution of CCND1 gene 
polymorphism G870A to breast cancer risk independently and in interaction with COMT 
gene Met108/158Val polymorphism. These polymorphisms were evaluated in two 
independent populations from Ontario, Canada, and Fi land. Both of these polymorphisms 
occurred frequently in the population controls: the frequency of CCND1 AA genotype was 
21.7% and 21.3%, and the frequency of COMT ValVal genotype 22.4% and 20.8% 
among the Canadian and Finnish samples. These frequencies are in line with earlier data 
published on these polymorphisms. 
The CCND1 high (AA) genotype had a significant association with breast cancer risk in 
both Canadian and Finnish samples. Three earlier studies with relatively small populations 
(200-500 cases) had found no significant association (Grieu et al. 2003, Krippl et al. 2003, 
Försti et al. 2004). Thus, our study was the first to show a significant independent impact 
of the CCND1 polymorphism on breast cancer predisposition in two separate, relatively 
large case control series. Shortly after our study, a Taiwanese study with 992 breast cancer 
patients and 960 controls showed that AA and AG genotypes were significantly more 
common among cases than controls, supporting the finding that the CCND1 high (A) 
allele contributes to breast cancer predisposition (Yu et al. 2008). CCND1 polymorphism 
has previously been shown to alter the enzymatic acivity of its protein product, and the 
protein encoded by the CCND1 high (A) allele has been hypothesized to produce a more 
stable protein than the low (G) allele. Cells with the more stable high enzymatic activity 
allele may remain under proliferative influence longer, thus giving a rationale for this 
variant in cancer predisposition. 
The COMT high (ValVal) genotype had an independent significant association with breast 
cancer risk in the Canadian but not in the Finnish series. A meta-analysis carried out on 
the reported case control studies in Caucasian breast cancer samples and noncancer 
controls showed a significant association of this COMT genotype with breast cancer risk 






Kocabas et al. 2002, Wedren et al. 2003, Ahsan et al. 2004, Sazci et al. 2004, Gaudet et al. 
2006, Onay et al. 2006, Akisik et al. 2007). Earlier terature has suggested the COMT 
high enzymatic activity genotype to have a protective role in the cell by accelerating the 
conversion of catechol estrogens into their proper methoxyestrogens. The enhanced 
activity has been postulated to reduce the chance of DNA damage caused by reactive 
oxygen species created by oxidation of estrogen. A recent study, however, reported 
noncompetitive negative feedback inhibition of CYP1A1 and CYP1B1 enzymes by 
methoxyestrogens (Dawling et al. 2003). According to this report, methoxyestrogens 
generated by COMT inhibit oxidation of the parent estrogen by CYP1A1 and CYP1B1. In 
addition, although one of the metabolites of COMT, namely 2-methoxyestrogen, is found 
to protect the tissues from cancer by inhibiting aniogenesis (Zhu & Conney 1998), the 
same product was also found to cause chromosome breaks and aneuploidy at increased 
concentrations (Tsutsui et al. 2000), suggesting the importance of balance of 
concentrations of any metabolites or enzymes in the estrogen metabolism. Thus, this data 
provides a rationale for the role of high COMT activity in breast cancer carcinogenesis. 
The combined effect of CCND1 and COMT genotypes on increased breast cancer risk was 
investigated, since these genes have complementary functional roles in the estrogen 
pathway. The results imply a genetic cross-talk betwe n the medium and high enzymatic 
activity allele combinations of CCND1 and COMT in breast cancer development. The 
functions of both CCND1 and COMT in the estrogen pathw y can explain the biological 
relevance of this combined effect. The reduced estrogen metabolization by the negative 
feedback of high COMT activity may result in increas d levels of estrogen, which in turn 
may lead to enhanced expression of CCND1. Because the CCND1 high (A) variant also 
encodes a more stable form of the protein, the cells containing this combination may be 
more susceptible to cell cycle progression and prolife ation. This suggestion warrants 
further experimental validation. The findings of our study imply that the individuals 
inheriting the combinations of high activity COMT and CCND1 alleles have relatively 
higher breast cancer risk probably due to simultaneously reduced estrogen metabolism and 
increased cell proliferation. The results also show an example of the potential role of 
combined effect of low penetrance variants on breast c ncer predisposition. Recently, a 
similar model of several low penetrance variants increasing individual risk has been 






6.4 Cyclin expression and tumor characteristics (IV , V) 
6.4.1 Cyclin E expression is elevated in aggressive  breast cancer (IV) 
In Studies II and III, the roles of cyclin D1 and E in familial breast cancer were evaluated. 
In Study IV, we further investigated cyclin D1 and E expression and their associations 
with tumor phenotype and survival. Study IV showed that high cyclin E expression 
correlates with an aggressive breast cancer phenotype, strengthening the role of high 
cyclin E in breast cancer with aggressive behavior. High cyclin E expression correlated 
with high grade, high Ki67 and cyclin A expression, ER and PR negativity, HER2 
positivity, large tumor size, and younger age at disease onset and had a significant 
association with a new entity, the so-called triple negative (ER-, PR-, and HER2-negative) 
breast cancer. In this study, high cyclin E was also more common among tumors with 
negative p53 immunohistochemistry, confirming the earli r finding of Lindahl et al. 
(2004) that tumors with high cyclin E had p53 insertions or deletions, and undetectable 
p53 expression. A potential explanation for this may be that chromosomal instability 
caused by cyclin E leads to inactivation of tumor suppressor p53. Medullary and ductal 
histology more often showed high cyclin E expression. The association with medullar 
histology has been described earlier, and this may be due to cyclin E’s ability to modulate 
the infiltrative behavior of the tumor (Berglund et al. 2005). 
6.4.2 Cyclin D1 correlates with high proliferation in estrogen receptor -
positive breast cancer (IV) 
The associations of cyclin D1 with histopathological features and with prognosis in breast 
cancer are not fully understood. Especially the association with proliferation and the 
mechanisms by which cyclin D1 drives cell cycle progression remain unknown. The most 
important finding of Study IV was that among ER-positive tumors high cyclin D1 
expression showed a strong significant correlation with high tumor grade and high cyclin 
A and E and Ki67 expression, but among ER-negative tumors, it associated with low 
grade and low Ki67 and cyclin E expression. Our study was the largest by far to examine 
these aspects and the first to show these differing associations in a large breast cancer 






Dienst et al. 1997, Han et al. 2003, Hwang et al. 2003, Jirström et al. 2005), although 
some studies have not supported this (Michalides et al. 1996, Umekita et al. 2002, Reis-
Filho et al. 2006). High cyclin D1 expression has al o been more common among 
hormone receptor-positive tumors, and in line with this, high cyclin D1 in our study 
showed a strong association with positive hormone rec ptor status. The low expression of 
cyclin D1 among medullary cancers indicates that cyclin D1 does not have a significant 
role among basal subtype or BRCA1 cancers. 
Experimental data have implied that in ER-positive br ast cancer cells cyclin D1 is needed 
to drive proliferation, while in ER-negative cells proliferation proceeds through other, 
cyclin D1-independent mechanisms (Loden et al. 2002). Our results support this view; we 
showed that proliferation in ER-positive tumors is mediated by cyclin D1, but in ER-
negative tumors is driven by other, cyclin D1-independent mechanisms. This finding is 
further supported by cyclin D1 and proliferation marker cyclin A having a high correlation 
in ER-positive but no correlation in ER-negative can ers. It is also in accordance with an 
earlier study suggesting that in the ER-negative breast cancer cell cycle regulation does 
not occur through cyclin D1 and ER (Neuman et al. 1997), but proliferation may be 
activated through deregulation downstream from the pRB node overexpressing cyclin E. 
In ER-positive breast cancer cells with a pathologically active cell cycle, the deregulated 
pathway causing cell cycle activation can be hypothesized to be cyclin D1-pRB, and in 
these cases cyclin E expression may be a physiological consequence of cell cycle 
activation. The cyclin D1-pRB pathway warrants further investigation to elucidate this 
hypothesis. If confirmed, this pathway may even provide a means for developing new 
targeted biological therapies. Promising results in MCF-7 breast cancer cells imply that 
pharmacological shutting down of the cyclin D1/CDK4 complex inhibits cell proliferation 
and could be a useful strategy for limiting tumor growth (Grillo et al. 2006). 
In conclusion, the results of Study IV suggest that proliferation is driven by different 
mechanisms in hormone receptor-positive and -negative breast cancers, and that cyclin D1 
has a particularly important role in the hormone-receptor positive breast cancer. These 
findings reveal new biological data on mechanisms of pr liferation and cell cycle control 






6.4.3 Cyclin B1 is associated with aggressive breas t cancer phenotype (V) 
Cyclin B1 expression in breast cancer was investigated in Study V. The results of Study V 
show that high cyclin B1 expression is common among breast cancers with aggressive 
behavior. High cyclin B1 expression was associated with large tumor size, positive nodal 
status, high grade, high Ki67, cyclin A, and cyclin E expression, and ER and PR 
negativity. Similar associations have been reported in one previous population (Kühling et 
al. 2003, Rudolph et al. 2003). One smaller study with 73 tumors (Winters et al. 2001) 
found no correlation between N, T, ER, and p53 statu  nd cyclin B1 expression, but this 
discrepancy may be explained by the small sample siz . High cyclin B1 expression 
correlated significantly also with HER2 positivity, and this, to our knowledge, has not 
been reported earlier and is consistent with an aggressive phenotype. Furthermore, in this 
study, high cyclin B1 was associated with p53 positivity, which is biologically relevant 
since p53 controls the cell cycle via cyclin B1 (Innocente et al. 1999). The results of Study 
IV show that multiple biological factors related to an active cell cycle are intercorrelated. 
6.5 Cyclin expression and breast cancer survival (I V, V) 
6.5.1 Associations of cyclin E and D1 with survival  (IV) 
High cyclin E was associated with poor overall survival in univariate but not in 
multivariate analysis. However, cyclin E was found to be an independent marker of poor 
metastasis-free survival. Most previous studies have reported an association between high 
cyclin E and poor outcome, but some studies have been unable to show an independent 
effect on poor survival. Our study supports the role f high cyclin E in aggressive breast 
cancer, but failed to confirm an independent prognostic role. 
Cyclin D1 expression did not correlate with survival in the whole patient material, but 
among ER-positive chemotherapy-naïve patients reveal d a trend towards poor metastasis-
free survival. This is in line with earlier findings since most studies to date have shown 
that cyclin D1 is not a prognostic factor in breast cancer. Instead, a role in tamoxifen 
resistance has been suggested. Our material was not designed to evaluate endocrine 






positive chemotherapy-naïve patients supports the idea that cyclin D1 may have an 
oncogenic role particularly in hormone receptor-positive breast cancer. 
6.5.2 High cyclin B1 predicts poor breast cancer su rvival (V) 
Study V shows that high cyclin B1 expression is a strong independent predictor of poor 
overall and metastasis-free survival. The associatin with poor outcome was stronger 
among chemotherapy-naïve patients. In multivariate analysis, high cyclin B1 predicted 
shorter overall survival, with RR 1.83 (P=0.05), and metastasis-free survival, with RR 
1.68 (P=0.04), and apart from positive nodal status and large tumor size was the only 
independent prognostic factor. Among patients receiving adjuvant chemotherapy, cyclin 
B1 was not an independent predictor of poor survival. Results were similar when ER 
positive/negative subgroups and patients of different age groups were analyzed separately. 
In our material, high cyclin B1 count was a stronger prognostic factor than proliferation 
markers cyclin A and Ki67, or cyclin E (Table 13). Furthermore, in multivariate analysis, 
among chemotherapy-naïve patients high cyclin B1 predicted metastasis with a stronger 
relative risk than tumor grade, PR, or HER2 status, and poor survival with as strong a risk 
as PR status and grade. The independent prognostic value of cyclin B1 was as strong as or 
even stronger than the risks with the commonly used biological markers in breast cancer. 
The independent relative risk for histological grade has been reported to be approximately 
1.70-3.20 (Simpson et al. 2000, Elston & Ellis 2002, Volpi et al. 2004), for HER2 2.56 
(Joensuu et al. 2003), and for tumor-related proteolytic factors uPA and PAI-1 in a pooled 
analysis of 18 patient populations 2.58-3.12 (Look et al. 2002). Tumor triple negative 
status has been associated with poor OS (RR 1.8) and with poor MFS (RR 1.5) (Dent et al. 
2007). Gene expression profiles have been suggested to add specificity to prognostic 
evaluation with traditional and immunohistochemical markers. In a validation study, the 
most extensively investigated profile, the 70-gene prognosis signature, predicted 
metastases with RR 2.13 (95% CI 1.19-3.82) and mortality with RR 2.63 (95% CI 1.45-
4.79) (Buyse et al. 2006). Thus, high cyclin B1 might be a biological risk predictor as 






Table 13 Relative risks for poor metastasis-free and overall survival among chemotherapy 
naïve-patients (cyclin B1, cyclin A, Ki67, cyclin E, and cyclin D1 dichotomized at the 
7th percentile). 
METASTASIS-FREE SURVIVAL OVERALL SURVIVAL
RR 95% CI P-value RR 95% CI P-value
Cyclin B1 3.51 2.05-6.01 <0.0005 3.74 1.96-7.12 <0.0005
Cyclin A 2.26 1.17-4.86 0.004 2.47 1.17-5.54 0.005
Ki67 1.67 0.97-2.88 0.06 1.90 1.01-3.58 0.05
Cyclin E 1.61 0.94-2.78 0.08 1.43 0.75-2.71 0.27
Cyclin D1 1.55 0.89-2.69 0.13 0.77 0.41-1.45 0.42  
Our study is the largest one to date showing an association between high cyclin B1 and 
poor outcome in breast cancer. A previous smaller study with stage I-II tumors revealed 
no association (Peters et al. 2004), and one with 109 tumors showed an association 
between poor survival and only nuclear staining (Suzuki et al. 2007). A study with 73 
tumors yielded a significant association (Winters et al. 2001). In the hitherto largest study 
with 332 tumors with a negative nodal status, cyclin B1 was associated with poor 
prognosis, but not in a multivariate analysis including Ki67 (Kühling et al. 2003). When 
273 tumors treated with surgery and postoperative radiation only were analyzed, cyclin B1 







Table 14 Studies evaluating the association between cyclin B1 and prognosis in breast cancer. 
Study Patients Univariate analysis Multivariate analys is
Winters et al. 2001 n=73 nuclear cyclin B1, OS: nuclear cyclin B1, OS:
RR 1.22, P=0.05 P=0.02
nuclear cyclin B1, RFS: nuclear cyclin B1, RFS:
RR 1.23, P=0.02 P=0.005
cytoplasmic cyclin B1, OS: cytoplasmic cyclin B1, OS:
RR 1.36, P=0.02 P=0.005
cytoplasmic cyclin B1, RFS: cytoplasmic cyclin B1, RFS:
RR 1.57, P=0.001 P<0.001
Kühling et al. 2003, n=332 OS: P=0.022 NS
Rudolph et al. 2004 MFS: P=0.021
n=273 CT- and ET-naïve patients: CT- and ET-naïve patients:
NS NS
CT- and ET-naïve CT- and ET-naïve
premenopausal patients: premenopausal patients:
OS: P=0.04 OS: significant
MFS NS MFS NS
Peters et al. 2004 n=56 NS NS
Suzuki et al. 2007 n=109 nuclear cyclin B1: nuclear cyclin B1:
significant association significant association
with both OS and MFS with both OS and MFS
Aaltonen et al. 2008 n=797 all patients, OS: all patients, OS:
RR 3.26, P<0.0005 RR 1.83, P=0.05
all patients, MFS: all patients, MFS:
RR 2.44, P<0.0005 RR 1.68, P=0.04
CT-naïve patients, OS: CT-naïve patients, OS:
RR 4.07, P<0.0005 RR 1.80, P=0.04
CT-naïve patients, MFS: CT-naïve patients, MFS:
RR 3.47, P<0.0005 RR 2.31, P=0.02
 
Cut-off values around the 7th decile gave the best s paration between slowly and rapidly 
proliferating breast cancers in our previous study (Ahlin et al. 2007). This cut-off value 
was effective for cyclin B1 as well. Cyclin B1 dichotomized at 5.6%, corresponding to the 
7th decile, gave a RR of 2.58 (95% CI 1.82-3.90, P<0.00 5) for poor OS and a RR of 2.48 
(95% CI 1.72-3.57, P<0.0005) for poor MFS. In our material, this cut-off value identifies 
a similar proportion of patients for the high-risk group and candidates for chemotherapy as 
the proportion of grade 3 tumors. 
Cyclin B1 expression may not be a pure proliferation marker, but may also reflect other 
biological properties of the tumor, e.g. genomic instability. This is supported by the fact 
that the median time to first event among patients ventually developing metastases was 
similar in patients with high and low cyclin B1 expression. High cyclin A and Ki67 






In conclusion, Study V shows that cyclin B1 is an independent predictor of poor overall 
and metastasis-free survival in breast cancer. If veri ied, cyclin B1 immunohistochemistry 
might provide a method that could easily be adapted for routine use as a prognostic marker 
in breast cancer. Furthermore, the lower risk ratios f r mortality or metastases among 
patients receiving adjuvant chemotherapy imply that igh cyclin B1 may indicate 
enhanced sensitivity to chemotherapy. 
By investigating critical cell cycle regulator protein cyclins, we revealed new aspects of 
breast cancer predisposition, pathogenesis, and cliical course. Cyclins E and D1 were 
shown to play a role in familial breast cancer. Differ ng cyclin D1 expression suggests 
different pathways to drive proliferation in estrogen receptor-positive and -negative breast 
cancers. Cyclin expression seems to aid in prognostic evaluation of breast cancer, and 







I. Cyclin A expression can be reliably assessed on TMA. The agreement of cyclin A 
results on TMA and traditional large sections as well as the reproducibility of two readers’ 
results are good. TMA is a method that can easily and reliably be adapted for routine use 
in large-scale analyses to evaluate cyclin expression and histopathological and prognostic 
associations in breast cancer. 
II. Tumors of familial non-BRCA1/2 patients more frequently have high cyclin D1 and 
low cyclin E expression than tumors of sporadic or BRCA1- or BRCA2–positive patients. 
The significantly different expression of cyclin E and D1 among familial non-BRCA1/2 
tumors may reflect that at least part of this group has unique biological characteristics and 
a genetic background that distinguishes it both from BRCA1 and BRCA2 tumors and from 
sporadic tumors. Cyclin E and D1 expression can functio  as a novel marker for 
predicting BRCA1 and BRCA2 mutations among familial breast cancer cases. Identifying 
novel biological characteristics that distinguish BRCA1 and/or BRCA2 mutation-positive 
from mutation-negative breast cancer families is of high clinical importance since adding 
tumor characteristics to models predicting the probability for BRCA mutation can help to 
make these models more accurate. 
III. The CCND1 G870A polymorphism is associated with increased breast cancer risk in 
two independent populations from Finland and Ontario, Canada. The risk for breast cancer 
is even greater in the combined genotype of high enzymatic activity genotypes of CCND1 
(AA) and estrogen metabolism enzyme COMT (ValVal), suggesting that these alleles act 
in combination and contribute to breast cancer progression. The biological relevance of 
this combined effect can be explained by their commn relationship with estrogen. 
IV. Cyclin E is associated with the aggressive breast cancer phenotype and is an 
independent predictor of poor metastasis-free survival. High cyclin D1 expression is 
associated with high tumor grade and high Ki67, cyclin A, and cyclin E expression in ER-
positive but with low tumor grade and low Ki67 expression in ER-negative breast cancer. 
These results imply that cyclin D1 has a controversial role, and proliferation is driven by 
different mechanisms in ER-positive and -negative br ast cancers. The results also 






In ER-negative cancers, by contrast, cyclin D1 appers to have no role in regulation of 
proliferation. These findings reveal new biological data on the mechanisms of 
proliferation and cell cycle control as well as on the pathogenesis of breast cancer, with 
also clinical implications for prognostic evaluation and possibly even for developing new 
targeted therapies for breast cancer in the future.  
V. High cyclin B1 expression correlates with high tumor grade, large tumor size, positive 
nodal status, estrogen and progesterone receptor negativity, positive HER2 and p53 status, 
high proliferation rate, high cyclin E expression, a d young age at diagnosis. This shows 
that cyclin B1 overexpression is common among breast c ncers with an aggressive 
phenotype and that multiple biological factors relat d to an active cell cycle are 
intercorrelated. 
VI. Cyclin B1 is an independent predictor of poor overall and metastasis-free survival in 
breast cancer. Apart from tumor size and nodal statu , cyclin B1 was the only independent 
marker of poor outcome among patients not given adjuvant chemotherapy. In our material, 
cyclin B1 was a more precise prognostic factor than proliferation markers cyclin A or 
Ki67 and predicted poor outcome better than tumor grade or HER2 or PR status. The 
relationship of cyclin B1 with breast cancer prognosis warrants further investigation, and 
if verified, this association suggests that cyclin B1 immunohistochemistry is a method that 
could easily be adapted for routine use, adding information to prognostic evaluations 
based on traditional prognostic markers. The lower risk ratios for mortality among patients 
receiving adjuvant chemotherapy suggest that high cyclin B1 expression may also reveal 
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